UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549~~STATES

~~Form~~SECURITIES ~~10-K~~AND EXCHANGE COMMISSION

xWashington, ~~Annual~~D.C. ~~Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~20549

~~For~~FORM ~~the fiscal year ended December 31, 2016~~10-K

~~o Transition Report pursuant to Section 13 or 15~~(d)Mark ~~of the Securities Exchange Act of 1934~~One)

For the transition period from __________ to __________

x	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2017

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to _________

Commission file number 333-208050

~~Commission~~MEDICO ~~file~~INTERNATIONAL ~~number~~INC. ~~333-208050~~(Exact name of registrant as specified in its charter)

MEDICO INTERNATIONAL INC. (Exact name of small business issuer as specified in its charter)

Nevada

37-1793037

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

Nevada	8052	37-1793037
187 E. Warm Springs Road, Suite B273, Las Vegas, NV		89119
(State or other jurisdictionof incorporation or organization)	(Primary Standard IndustrialClassification Number)	(IRS EmployerIdentification Number)
(Address of principal executive offices)		(Zip Code)

~~187~~Registrant’s E.telephone ~~Warm~~number, ~~Springs~~including ~~Road,~~area ~~Suite~~code: ~~B273~~(86) 138 1833 3008

~~Las~~Securities ~~Vegas,~~registered NVpursuant ~~89119~~to Section 12(b) of the Act:

~~(Address~~Title of ~~principal~~Each ~~executive~~Class ~~offices)~~Name of Each Exchange On Which Registered N/A N/A

Securities registered pursuant to Section 12(~~732~~g) ~~383-9118~~of the Act:

~~(Issuer's telephone number)~~N/A

~~None~~(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities ~~registered~~Act. ~~under~~Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes ¨ No x Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (bor for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days. Yes x No ¨ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-K (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No x Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

~~None~~Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company x Emerging Growth Company x

~~Securities~~If ~~registered~~an ~~under~~emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 1213(ga) of the Exchange Act. ¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x The aggregate market value of Common Stock held by non-affiliates of the Registrant on June 30, 2017, the last business day of the Registrant’s most recently completed second fiscal quarter was $Nil, based on there being no public market for the Registrant’s stock. Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date. 3,697,000 common shares as of January 14, 2019

~~Indicate~~DOCUMENTS byINCORPORATED ~~check~~BY ~~mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x~~REFERENCE

~~Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act~~None. ~~Yes ¨ No x~~

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Yes ¨ No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The aggregate market value of the registrant’s outstanding common stock held by non-affiliates of the registrant computed by reference to the price at which the common stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was $0. The registrant’s common stock has not been traded in the public market.

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 3,697,000 common shares issued and outstanding as of June 12, 2017.

TABLE OF CONTENTS

		Page
Item 1.	Business	3
PART I
Item 1A.	Risk Factors	5
Item 1.	Description of Business.		3
Item 1B.	Unresolved Staff Comments	5
Item 1A.	Risk Factors.		9
Item 2.	Properties	5
Item 1B.	Unresolved Staff Comments.		17
Item 3.	Legal Proceedings	6
Item 2	Description of Property.		18
Item 4.	Mine Safety Disclosures	6
Item 3.	Legal Proceedings.		18
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	6
Item 4.	Mine Safety Disclosures.		18
Item 6.	Selected Financial Data	7
PART II
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	7
Item 5.	Market for Common Equity and Related Stockholder Matters.		19
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	9
Item 6.	Selected Financial Data.		20
Item 8.	Financial Statements and Supplementary Data	10
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.		20
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	22
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.		23
Item 9A.	Controls and Procedures	23
Item 8.	Financial Statements and Supplementary Data.		24
Item 9B.	Other Information	23
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.		34
Item 10.	Directors, Executive Officers and Corporate Governance	24
Item 9A.	Controls and Procedures		34
Item 11.	Executive Compensation	26
Item 9B.	Other Information.		35
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	28
PART III
Item 13.	Certain Relationships and Related Transactions, and Director Independence	28
Item 10	Directors, Executive Officers, Promoters and Control Persons of the Company.		36
Item 14.	Principal Accounting Fees and Services	29
Item 11.	Executive Compensation.		37
Item 15.	Exhibits, Financial Statement Schedules	30
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.		38
Item 13.	Certain Relationships and Related Transactions, and Director Independence.		39
Item 14.	Principal Accounting Fees and Services.		39
PART IV
Item 15.	Exhibits		40
Signatures

2 Table of Contents

PART I

Item 1. ~~Description of~~ Business

~~FORWARD-LOOKING~~Forward ~~STATEMENTS~~Looking Statements

This annual report contains forward-looking statements. These statements relate to future events or our future financial performance. ~~These~~In ~~statements~~some ~~often~~cases, you can beidentify ~~identified~~forward-looking statements by ~~the~~terminology ~~use of terms~~ such as "“may”," ~~"will~~“should”," ~~"expect~~“expects”," ~~"believe~~“plans”," ~~"anticipate~~“anticipates”," ~~"estimate~~“believes”," ~~"approximate"~~“estimates”, “predicts”, “potential” or "“continue,"” or the negative ~~thereof.~~of Wethese ~~intend~~terms ~~that~~or ~~such~~other ~~forward-looking~~comparable ~~statements~~terminology. beThese ~~subject to the safe harbors for such~~ statements. Weare ~~wish~~only topredictions ~~caution~~and ~~readers~~involve ~~not~~known toand ~~place~~unknown ~~undue~~risks, ~~reliance~~uncertainties onand ~~any~~other ~~such forward-looking statements~~factors, ~~which~~including ~~speak only as of~~ the ~~date~~risks ~~made. Any forward-looking statements represent management's best judgment as to what may occur~~ in the ~~future.~~section ~~However,~~entitled ~~forward-looking~~“Risk ~~statements~~Factors” ~~are~~that ~~subject~~may tocause ~~risks,~~our ~~uncertainties~~or ~~and important factors beyond~~ our ~~control~~industry’s ~~that could cause~~ actual results, ~~and~~levels ~~events to differ materially from historical results~~ of ~~operations~~activity, ~~and~~performance ~~events and those presently anticipated~~ or ~~projected.~~achievements Weto ~~disclaim~~be ~~any~~materially ~~obligation~~different ~~subsequently~~from ~~to revise~~ any ~~forward-looking~~future ~~statements~~results, tolevels ~~reflect events or circumstances after the date~~ of ~~such~~activity, ~~statement~~performance or toachievements ~~reflect~~expressed ~~the~~or ~~occurrence~~implied ofby ~~anticipated~~these orforward-looking ~~unanticipated events~~statements.

~~Medico~~Although ~~International~~we ~~Inc.~~believe (that the ~~“Company”)~~expectations ~~was~~reflected ~~incorporated~~ in the ~~State~~forward-looking ofstatements ~~Nevada~~are onreasonable, ~~September~~we 18cannot guarantee future results, ~~2015~~levels of activity, performance or achievements. ~~The~~Except ~~Company’s~~as ~~registration~~required ~~statement~~by onapplicable ~~Form~~law, ~~S-1~~including ~~was~~the ~~declared~~securities ~~effective~~laws byof the ~~Securities~~United ~~and~~States, ~~Exchange~~we ~~Commission~~do onnot ~~December~~intend ~~22,~~to ~~2015~~update any of the forward-looking statements to conform these statements to actual results.

~~The~~Our ~~Company~~financial ~~was~~statements ~~formed~~are ~~and~~stated ~~organized~~in ~~for~~United ~~the~~States ~~purposes~~Dollars ~~of acting as the holding company for Smile More Holding Pte. Ltd., which is a private Singapore corporation~~ (~~referred to herein as “Smile Central”~~US$). ~~Smile Central is a dental company employing the latest techniques in oral care~~ and ~~oral~~are ~~surgery~~prepared in ~~Singapore.~~accordance ~~Formed~~with inUnited ~~2014,~~States ~~Smile~~Generally ~~Central~~Accepted ~~has~~Accounting ~~expanded to 5 locations in population-dense high foot traffic residential centers all over Singapore~~Principles.

~~Smile~~In ~~Central's~~this ~~business~~annual ~~objectives~~report, unless otherwise specified, all dollar amounts are toexpressed ~~improve~~in ~~techniques~~United States dollars and ~~achieve~~all references to “common shares” refer to the ~~following:~~common shares in our capital stock.

-As ~~make~~used in this current report and unless otherwise indicated, the ~~existing~~terms ~~treatment~~“we”, ~~more~~“us” ~~effective;~~and “our” mean Medico International Inc., unless otherwise indicated.

-General ~~decrease the recovery time of patients; and~~Overview

-Medico ~~reduce~~International Inc. was incorporated in the ~~cost~~State of ~~innovative/cutting~~Nevada ~~edge~~on September 18, 2015. Our company was formed and organized for the purposes of acting as the holding company for Smile More Holding Pte. Ltd., a private Singapore corporation (referred to herein as “Smile Central”) engaged in the dental ~~procedures~~industry. Due to continued consolidated losses experienced by our company as a result of the losses of Smile Central, our board of directors believed it was in the best interests of our company and our shareholders to dispose of Smile Central.

~~Smile~~Our ~~Central~~company’s isformer ~~designed~~majority toshareholders, ~~enhance~~Eminent ~~this~~Healthcare ~~market~~Pte. ~~with~~Ltd. ~~its~~and ~~small~~Multi ~~core~~Care ofPte. ~~eminent~~Ltd. ~~dentists,~~(the ~~key~~“Majority ~~employees~~Shareholders”), ~~and~~became ~~strong~~shareholders ~~outsourced~~of ~~partners.~~our ~~Management~~company ~~believes~~in ~~that~~2015 by exchanging all of the outstanding share capital of Smile Central ~~has~~(“Smile aShares”) ~~business~~for ~~model~~3,000,000 ~~that~~shares isof ~~easily~~our ~~scalable~~company’s tocommon ~~effect~~stock ~~rapid~~(the ~~growth~~“Medico Shares”) and ~~expansion~~the Majority Shareholders desired to re-acquire the Smile Shares.

3On ~~Table~~June 5, 2017, we closed the transactions under the Share Exchange Agreement (“Share Exchange Agreement”) by and between our company, Eminent Healthcare Pte. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited company, for the sale of ~~Contents~~all of the issued and outstanding ordinary shares of our company’s 100% wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (the “Stock Purchase”). Prior to the closing of the Stock Purchase, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. were our company’s majority shareholders. Liew Min Hin, our former Chief Financial Officer and former member of the Board of Directors, owns 100% of Eminent Healthcare Pte. Ltd., and is the father of Dr. Daniel Liew, our former Chief Executive Officer and former member of the Board of Directors.

~~Recent~~Pursuant ~~Developments~~to the Share Exchange Agreement, in consideration for transferring the Smile Shares to the Majority Shareholders and waiving the Intra-Company Loan, our company received all of the rights, interests, claim and title in that certain US patent known as “Method for diagnosing malignancy in pelvic tumors”, US Patent No. 6,112,108 (the “Patent”), which Targeted Solutions Global Limited, a United Kingdom Private limited company (“TSG”) had the right and ability to deliver to our company and in connection with the closing of the Share Exchange Agreement, Jiang Chun Yan was appointed as the CEO and sole member of our company’s Board of Directors.

~~Due~~3 toTable ~~the continued consolidated losses experience by the Company as the result~~ of the losses of the Company’s wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (“Smile Central”), which included $232,769 for the fiscal year ended December 31, 2015, $801,760 for the fiscal year ended December 31, 2106, the Board of Directors of the Company believed it was in the best interests of the Company and its shareholders to dispose of Smile Central. In addition, the Company had provided Smile Central with over $600,000 in intra-company loans (the “Intra-Company Loan”). Contents

~~The~~In ~~Company’s former majority shareholders~~addition, ~~Eminent~~under ~~Healthcare~~the ~~Pte.~~Share ~~Ltd.~~Exchange ~~and~~Agreement, ~~Multi~~TSG ~~Care~~received ~~Pte.~~from ~~Ltd. (~~the “Majority Shareholders~~”),~~ ~~became shareholders of~~ the ~~Company in 2015 by exchanging all of the outstanding share capital of Smile Central (“Smile Shares”) for 3,000,000 shares of the Company’s common stock (the “~~Medico Shares”) and the Majority Shareholders ~~desired~~received to$200,000 ~~re-acquire~~from ~~the Smile Shares~~TSG.

OnThe ~~June~~effect 5,of ~~2017,~~ the ~~Company~~transactions ~~closed~~set ~~the~~forth ~~transactions~~in ~~under~~ the Share Exchange Agreement (“is ~~Share~~that ~~Exchange~~commencing ~~Agreement”)~~June ~~by and between the Company~~5, ~~Eminent~~2017 ~~Healthcare~~our ~~Pte. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited~~ company, ~~for~~will ~~the~~no ~~sale~~longer ofown ~~all of the issued~~ and ~~outstanding~~operate ~~ordinary~~dental ~~shares~~clinics ofin ~~the~~Singapore ~~Company’s~~but ~~100%~~will ~~wholly-owned~~focus ~~subsidiary,~~its ~~Smile~~efforts ~~More~~in ~~Holdings Pte. Ltd., a Singaporean corporation (~~the ~~“Stock~~area ~~Purchase”). Prior to the closing~~ of ~~the~~cancer ~~Stock~~diagnostics ~~Purchase,~~tools ~~Eminent~~in ~~Healthcare~~connection ~~Pte.~~with ~~Ltd. and Multi Care Pte. Ltd. were~~ the ~~Company’s majority shareholders~~Patent. Liew Min Hin, the Company’s former Chief Financial Officer and former member of the Board of Directors, owns 100% of Eminent Healthcare Pte. Ltd., and is the father of Dr. Daniel Liew, the Company’s former Chief Executive Officer and former member of the Board of Directors.

~~Pursuant~~Our toaddress ~~the~~is ~~Share~~187 ~~Exchange~~E. ~~Agreement,~~Warm inSprings ~~consideration for transferring the Smile Shares to the Majority Shareholders and waiving the Intra-Company Loan~~Road, ~~the~~Suite ~~Company received all of the rights~~B273, ~~interests,~~Las ~~claim and title in that certain US patent known as “Method for diagnosing malignancy in pelvic tumors”~~Vegas, USNV ~~Patent No~~89119. ~~6,112,108~~Our ~~(the~~telephone ~~“Patent”),~~number ~~which~~is ~~Targeted Solutions Global Limited, a United Kingdom Private limited company~~ (~~“TSG”~~732) had the right and ability to deliver to the Company and in connection with the closing of the Share Exchange Agreement, Jiang Chun Yan was appointed as the CEO and sole member of the Company’s Board of Directors383-9118.

InWe ~~addition,~~do ~~under~~not ~~the~~have ~~Share~~any ~~Exchange Agreement, TSG received from the Majority Shareholders the Medico Shares and the Majority Shareholders received $200,000 from TSG~~subsidiaries.

~~The~~We ~~effect~~have ofnot ~~the~~ever ~~transactions~~declared ~~set~~bankruptcy, ~~forth~~been in ~~the Share Exchange Agreement is that commencing June 5~~receivership, ~~2017~~or ~~the~~involved ~~Company will no longer own and operate dental clinics~~ in ~~Singapore~~any ~~but~~kind ~~will focus its efforts in the area~~ of ~~cancer~~legal ~~diagnostics tools in connection with the Patent~~proceeding.

~~The~~Our ~~below~~Current ~~information pertains to the operations of Smile Central.~~Business

~~The~~We ~~Company~~have begun to focus our efforts in the area of cancer diagnostics tools in connection with the patents acquired in the Share Exchange Agreement completed in June 2017.

Through 2016 Smile Central operated 5 dental clinics throughout Singapore, with each clinic meeting its respective revenue and profit targets every quarter so far. Since 2015, Smile Central has expanded its operations by adding a new dental center adjacent to its Aljunied clinic and increasing the number of dental operating chairs at its Jurong location from two (2) to six (6). The facilities for the new dental center in Aljunied have been leased and equipment has been purchased. Smile Central is currently completing renovations to the facilities. Its business model focuses on recruiting qualified and experienced dentists, supported by well-trained clinic support staff. Our dentists have post-graduate training in the fields of endodontics, orthodontics, periodontics, prosthodontics, paedodontics, oral surgery and implant dentistry. Hence, we are able to carry out procedures ranging from the routine cleaning and filling to the most complex ones involving aesthetics and surgery.Services

InThe ~~addition~~Company todoes ~~basic~~not ~~dental~~currently ~~care~~offer any products or services, ~~our~~and ~~strengths~~is ~~include:~~currently reviewing future prospective products and services.

·Our ~~Invisible braces for the young and for working adults. · Dental implants to rehabilitate functionality.~~Market

~~Smile~~The ~~Central~~Company ~~positions~~is ~~itself~~reviewing asits anprospective affordable dental chain where patients of all demographics can afford basic and complex dental care with government Medisave claims and government-aided subsidies like the Community Health Assist Scheme and the Pioneer Generation subsidy for the elderlymarket.

~~Planned Services (In Addition to Current List of Services)~~Strategy

4The ~~Table~~Company ofis ~~Contents~~currently reviewing a new strategy for research and development related to the patents acquired in June 2017.

~~Among some of the new techniques and procedures Smile Central is looking to incorporate are:~~Seasonality

·Although ~~Laser~~our ~~Teeth~~operating ~~Whitening~~history ·is ~~Aesthetic Implants and Implant Maintenance · Laser Surgery - used to perform soft-tissue surgery~~limited, ~~including~~we ~~removing~~have ~~tumors~~not ~~and~~experienced ~~lesions~~a ~~from~~seasonal ~~the~~business soft tissues of the mouth, as well as tooth cleaning and plaque removal · Oral and Maxillofacial surgery - the treatment of many diseases, injuries and defects in the head, neck, face, jaws and the hard and soft tissues of the Oral (mouth) and Maxillofacial (jaws and face) regioncycle.

~~Goals for Expansion~~Competition

~~According~~Once to the ~~Singapore~~Company Dental Council, the current dentist-to-population ratio in Singapore is 1:2,960, a ratio we feel is indicative of the scope of expansion possible for the dental industry. In comparison, for 2013-2014, the statistics for the dentist-population ratio in England is around 1:2,000, with some areas having as high a ratio as 1:1,682. We feel that due to the highly-fragmented dental market in Singapore, the market has ~~room~~determined toits ~~grow~~future ~~by another 40-50%~~strategy, ~~with 15% yearly gains possible for at least~~ the ~~next~~Company’s 5competition years. Management is currently in talks with graduate dentists from overseas (predominantly from the UK and Australia) to employ them to staff the new locations. As is the current practice, each location will be ~~overseen~~evaluated by a senior partner who is also a practicing specialist. Management hopes to staff each new location initially with 3 dentists working under the senior specialist. Leveraging on the existing expertise and business partnerships with suppliers, the new locations will be set up in ~~the~~further ~~most cost-efficient manner in order to capitalize on the current opportunities immediately~~detail.

~~Management~~Compliance also currently has in place a program of sending selected high-performing dentists under its employment to increase their knowledge and expertise through seminars, courses, further study and specialization. This is in line with ~~its~~Government ~~policy of training the dentists to assume senior partner positions at new locations.~~Regulation

~~Direct~~The ~~Competition~~Company is currently in compliance with all government regulations. The Company will be continually reviewing all applicable government regulations related to a new strategy being evaluated by the Company.

~~The~~Research ~~direct competitors of Smile Central are the dental companies with 3-10 clinics in their stable. Smile Central is already leveraging on economies of scale to provide a more professional~~ and comfortable experience for patients at a lower cost, and should see off competition from the individual standalone clinics. The increased suite of services at the new locations should position it above ordinary clinic chains as it is able to provide a well-rounded range of services.Development

5We ~~Table~~have ofincurred ~~Contents~~$Nil in research and development expenditures over the last two fiscal years.

~~Future~~Intellectual ~~Competition~~Property

~~Future~~We ~~competition~~do ~~will~~not ~~come~~currently inhave ~~the~~any ~~form~~intellectual ~~of new clinic chains who consolidate to grow, or chains which acquire standalone clinics to increase their size~~property. Management feels that with constant learning and innovation, Smile Central will be able to stay ahead of the competition by offering continually advanced and modern services and equipment at a competitive price point.

~~Competitive~~4 ~~Analysis~~Table of Contents

Overall, management contends that the Company competes by being a leading provider of a full line of technologically advanced procedures and techniques, supported by the exceptional core managerial team and the able dentists and staff. One of the primary areas of competition is for diligent and conscientious dentists who are personable and able to form good client-doctor relations. There is also strong competition for more senior dentists with their own clientele.Employees

~~With~~Our ~~our~~company ~~many~~has ~~opportunities~~no ~~for~~employees. ~~continuing~~Our ~~education~~sole ~~learning~~director and officer is donating their time to the development of our company, weand ~~believe~~intends weto do whatever work is necessary to bring us to the point of earning revenues. We estimate that our sole officer and director will be able to ~~attract~~complete ~~young~~his ~~dentists~~required ~~with~~work aand ~~view~~complete whatever work is necessary by spending 20 hours per week without lending our company additional funds. If this is not the case and additional time and funds will be required then he is willing to acommit ~~long~~additional ~~career~~time and funds although he has no commitment or contractual obligation to do so. We have no other employees, and do not foresee hiring any additional employees in the ~~company~~near future. ~~Dentists~~We ~~with~~will ~~good~~be PRengaging ~~skills~~independent ~~should~~contractors ~~also~~to bedesign ~~identified~~and develop our website and ~~recruited~~manage our internet marketing efforts.

~~Target~~WHERE ~~Market~~YOU ~~Profile~~CAN FIND MORE INFORMATION

~~Smile~~You ~~Central~~are isadvised ~~rolling~~to ~~out~~read athis ~~plan~~Form 10-K in conjunction with other reports and documents that we file from time to ~~target~~time ~~different~~with ~~segments~~the SEC. In particular, please read our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the ~~market~~SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

· We actively recruit dentists who are good with kids and who are parents themselves, to cater to the pediatric dental market. Frequently the parents of the kids also come in for treatment when we attend to their kids.

· We target the young professionals who want a comfortable space to have their dental treatment.

· Our dentists take care of the senior citizens by educating them on oral hygiene and providing subsidized oral care.

· There is ethnic diversity in our dentists and staff - they hail from different ethnic groups and are multilingual so as to cater to every segment of the market.

Future Markets

Smile Central plans to build its Singapore network of clinics until it perceives that the Singapore market is saturated. Following that, Smile Central will look to the neighboring countries for expansion, as it believes the level of dental care is lacking in the developing countries around Singapore.

At the same time, moving more towards dental surgery and aesthetics will see the revenues increase as these treatments are more expensive, with some aesthetic surgery going up to $40,000 per patient. 3D Radiography is another segment management is looking to go into - in 3D Radiography, a large volumetric 3D image is created in a single 14 second 3D scan that provides the highest resolution with the lowest radiation dose. This is safer and more comprehensive than traditional radiography, and as the population becomes more savvy and affluent, more would turn towards this rather than traditional radiography.

Governmental Approvals

Smile Central operates within a very strict governmental approval framework and all treatment methods and procedures are completely compliant with governmental laws and guidelines.

6 Table of Contents

Demographics

Singapore’s dental services and equipment and supplies market is expected to grow in tandem with the city state’s reputation as the region’s healthcare hub and center of healthcare excellence. Singapore is ranked sixth out of 191 countries globally and the best in Asia by the World Health Organization.

As a multi-faceted medical hub, Singapore attracts a growing number of medical professionals and multi-national healthcare-related companies from various parts of the world to share and exchange their expertise, conduct healthcare-related research and training as well as host international conferences and events.

With Singapore's well-developed infrastructure and robust medical ecosystem, healthcare providers in Singapore are constantly strengthening their medical capabilities through professional exchanges and access to innovation in medical technology.

In Singapore, medical travelers can receive quality medical care in an environment that is safe and welcoming, with no uncertainties from political instability, social unrest, or worries about poor health safety. This is on top of an efficient transportation system, wide range of accommodation options, and a wide variety of leisure offerings to enhance the experience in Singapore.

Singapore's quality healthcare, as one of the best in the world, is internationally recognized.

· Ranked first for most efficient healthcare system, out of 51 countries, in 2014 by Bloomberg.

· Ranked second in the world for health-care outcomes according to The Economist Intelligence Unit (EIU) in 2014.

· Ranked first as a global favorite medical tourism destination in PHD Chamber Medical and Wellness Tourism Report 2013.

	·	21 hospitals and medical centres and medical organizations in Singapore have obtained the Joint Commission International (JCI) accreditation.
	·	Singapore's blood supply ranks among the safest in the world. Blood Services Group HSA (previously known as Singapore's Centre for Transfusion) was appointed a World Health Organization (WHO) Collaborating Blood Centre for Transfusion Medicine for the Western Pacific Region in 1992.

Singapore's increased emphasis on medical tourism has seen the number of tourists traveling to Singapore for healthcare purposes grow significantly. The total medical tourism receipts came in at $832 million in 2013, up from $383 million in 2004, and Singapore's medical tourism market is expected to grow 8.3% per annum from now to 2018.

Singapore’s dental practitioners have seen a steady demand for more complex and specialty dental procedures from foreign visitors who also come here for medical consultation. The country continues to strive to provide first class healthcare systems and facilities to its residents and the international patient market.

The medical and dental sector is also expected to see gains due to the increasing population. The population of Singapore is now 5.4 million, and this is expected to rise to 6.9 million in 2030.

7 Table of Contents

Market Demand

The general status of dental and oral hygiene of Singaporeans is good. Attributing to this success is the Singapore government’s fluoridation of potable water initiative since 1958 and the widespread use of fluoridated toothpaste among the general population. As such, the dental work done by dental practitioners has shifted from the traditional “drill and fill” regime to one that focuses on enhancing the patient’s aesthetic appearance.

The emphasis of the public healthcare service is in preventive dentistry targeted at pupils in schools. Dental care begins with preventive dentistry promoted through the Singapore Health Promotion Board, a statutory board tasked to promote a good and healthy lifestyle among Singaporeans. The Board targets students through a network of 200 static clinics located in schools as well as 30 mobile dental clinics. This plus fluoridation of potable water and availability of fluoridated toothpaste has greatly diminished dental decay and tooth loss.

Singapore provides some of the most advanced dental care in the region. With the third highest GDP per capita income in the world, Singaporeans' demand for the best and most sophisticated dental care is strong. According to a report that highlighted the results of a survey conducted by the Singapore Dental Association, nearly 45% of the population visits the dentist at least twice a year. They spend an average of US$80 for a visit to the dentist.

As an affluent nation, more and more patients are seeking treatment for their children early in the hope of arresting any potential problems with their teeth. More parents are bringing their children to see orthodontists before they lose their baby teeth. Teenagers and adults too are seeking corrective treatments to improve the alignment of their teeth.

Designer and/or transparent braces are popular and appeal to the more aesthetically-conscious and affluent. Costs for such treatments are in the thousands of dollars.

There has also been an increased awareness of oral and dental hygiene. More Singaporeans have adopted a more rigorous approach to oral care by incorporating flossing and gargling with a mouthwash to their typical routine of twice-a-day brushing. Schools have been instrumental in reinforcing this to the children.

Besides serving a more affluent and demanding resident population, dental practitioners have also seen a marked increase in foreign patients seeking dental treatment in Singapore. Wealthy patients from Indonesia, Brunei, Thailand, Malaysia, Philippines, Hong Kong, Cambodia, China and Vietnam began to visit Singapore for medical care in the 1980s. According to a news report, these patients are not looking for a quick clean or check-up, they come for treatments that include cosmetic dentistry that arrest problems of discolored teeth, gaps between teeth, unsightly old crowns and reconstructive work which can cost up to US$60,000.

Singaporean dentists do a lot of overseas teaching and are involved in overseas conferences. They are increasingly seen as experts in their field and are sought after as panelists at dental conferences, to do product demonstrations and as key opinion leaders. According to leading implant suppliers, implants are the fastest growing segment in the global dental market with an annual growth rate of 18-20 percent.

Many dental GPs are improving themselves through workshops and courses and the popular topics include implants and cosmetic dentistry. Cosmetic dentists are now seen as the “plastic surgeons of the dental sector”.

As Singaporean dental practitioners strive to provide more value-added consultations, some are providing their patients more holistic medical care by offering the option for oral cancer screening. Oral cancer is ranked 11th in the list of most common cancers in Singapore, based on information available from the Ministry of Health. Due to the anxiety that may be experienced by patients, this test is conducted selectively only when the patient displays high-risk symptoms and after the dental practitioner provides the appropriate counseling.

8 Table of Contents

Property

Our subsidiary, Smile Central, leases office space for each of our six (6) clinics. The table provided below summarizes the monthly rental cost, before applicable taxes, in Singapore dollars, and the tenancy period for each lease.

Clinic	Rental per mth		Tenancy Period
Aljunied	$	7,000	Aug 2014 – Jul 2017
Aljunied – Dental Lab	$	2,000	May 2015 – May 2017
Jurong	$	34,000	Sep 2015 – Sep 2018
Hougang	$	19,916	May 2015 – May 2018
HougangCentral	$	6,500	Apr 2014 – Apr 2016
SCD Centre	$	20,000	Aug 2016 – Aug 2019
Toa Payoh	$	16,000	Apr 2015 – Mar 2018

Employees

Smile Central employs sixty (60) employees, of which 49 are full-time employees, 11 are part-time employees, 3 full-time doctors (including the Company’s former executive officers, Dr. Liew and Dr. Chew) and 8 contracted doctors.

Item 1A. Risk Factors

WeAs ~~have~~ a ~~history~~“smaller ofreporting ~~losses~~company”, ~~and~~we ~~may~~are ~~never~~not berequired ~~profitable~~to provide the information required by this Item.

WeItem ~~have an accumulated deficit totaling $(1,161,700), as of December 31, 2016, and we are not profitable~~1B. ToUnresolved ~~date~~Staff our operations have not generated sufficient operating cash flows to pay for the expenses we incur on a current basis. We may not be able to successfully keep or grow our businesses or achieve profitability from our operations in the near future or at all.Comments

~~Among~~As ~~other~~a ~~things~~“smaller reporting company”, ~~our~~we ~~ability~~are not required to ~~achieve~~provide ~~sustainable~~the ~~profitability~~information isrequired ~~dependent~~by ~~on:~~this Item.

·Item Successful marketing and sale of our dental services and plan; · Our ability to acquire or open additional dental practices and operate them profitably; · Our ability to develop additional services and plans to serve dentists and their patients2. Properties

~~There~~Our ~~can~~address beis no187 ~~assurance~~E. ~~that~~Warm weSprings ~~will~~Road, ~~achieve~~Suite ~~sustainable~~B273, ~~profitability~~Las Vegas, NV 89119. Our offices are provided at no cost to our company.

95 Table of Contents

~~Our~~PART ~~cash reserves are not sufficient to pay the amounts owing on outstanding obligations.~~II

At December 31, 2016, we had $2,160,082 in current liabilities and working capital deficit of $(1,120,357). We do not have sufficient reserves to pay the amounts owing. As a result, no assurance can be given that the Company will have the resources to repay any or all of its current obligations. The failure of the Company to pay its obligations will have a material adverse effect on the Company, including the possibility of the Company ceasing to conduct operations.

Our net revenue may be adversely affected by changes in the government Medisave program and the Community Health Assist Scheme program or CHAS.

Our clinics are largely dependent upon reimbursements from the Singapore government insurance reimbursement programs known as Medisave and CHAS. The government of Singapore could at any time act to reduce Medisave and/or CHAS reimbursement rates in response to budgetary shortfalls. These reductions would generally be passed on to our practices and negatively affect our revenue and operating results.

Qualification to be able to participate in the Medisave and CHAS reimbursement programs can take up to three (3) months and limits our ability to open new clinics.

Part of our plan to become profitable includes opening additional dental clinics in Singapore. Our ability to quickly open clinics in a desirable location can be hindered by the amount of time that it takes for a new clinic to become qualified by the government to participate in the Medisave and CHAS reimbursement programs, which can take up to three (3) months. This type of delay could give other competing, established dental practices an advantage over us and impede our ability to enter into a given market.

RISKS RELATED TO REGULATORY MATTERS

Our clinics are subject to extensive laws and regulations. If we fail to comply with existing or new laws or regulations, we could suffer civil penalties.

The practice of dentistry is highly regulated. Our operations are subject to extensive laws, regulations, licensing requirements and guidelines set by the Ministry of Health (“MOH”) and the Singapore Dental Council (“SDC”), including regulations pertaining to our operations, the qualifications and conduct of clinical personnel, billing and reimbursement and the privacy and security of protected health information. Although we strive to maintain a legally-compliant business, our operations may not be in compliance with certain laws or regulations, as written or as may be interpreted. Failure to comply with laws and regulations may cause us to incur civil penalties, fines, shutting down of a clinic, or revocation of dentist practicing certificate. This would significantly limit our ability to operate our business. In addition, we could be excluded from participating in the Medisave and CHAS reimbursement programs.

Guidelines set by MOH can be changed at the MOH’s discretion, which could result in significant cost and potentially loss of time to service patients.

Most of our equipment is subject to guidelines set by the MOH regarding minimum requirements, which can change at the MOH’s discretion. In the event that the MOH’s guidelines are revised, we may be required to replace expensive equipment with new equipment, which would represent a significant new expense incurred by each of our clinics. These changes could occur at any time.

Our business operations could be interrupted by problems with our information systems.

Our business is dependent on information systems for operational processes, financial information and our billing operations. Our information system could be vulnerable to damage or interruption from computer viruses, human error, natural disasters, tele-communications failures, intentional acts of vandalism and similar events. A significant or prolonged interruption in our computer network, data center or software applications could have a material adverse effect on our business, financial condition and results of operations.

10 Table of Contents

A catastrophic event may significantly limit our ability to conduct business as normal.

We operate a complex, geographically dispersed business. Disruption or failure of networks or systems, or injury or damage to personnel or physical infrastructure, caused by a natural disaster, public health crisis, terrorism, cyber attack or other catastrophic event may significantly limit our ability and that of the affiliated practices to conduct business as normal, including our ability to communicate and transact with the affiliated practices, as well as with suppliers and vendors, and the ability of the affiliated practices to provide dental care to patients. We are not adequately insured for losses and disruptions caused by catastrophic events, and we may not have a sufficiently comprehensive enterprise-wide disaster recovery plan in place.

RISKS RELATED TO OUR COMMON STOCK

An active trading market for our common stock may not develop, and you may not be able to resell your shares of our common stock at or above the initial public offering price.

Although our common stock has been approved for listing on OTCQB, an active trading market for our shares has not developed and may never develop or be sustained. The initial public offering price of our common stock was arbitrarily determined by our Chief Executive Officer. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell.

The market price for our common stock will likely be volatile because of several factors, including a limited public float.

The market price of our common stock is likely to be highly volatile because there has been no public trading market for our stock. If our stock is approved for trading on the OTCQB, of which there is no guarantee, we will most likely have limited float, which causes trades of small blocks of stock to have a significant impact on our stock price. You may not be able to resell shares of our common stock following periods of volatility because of the market’s adverse reaction to volatility.

Other factors that could cause such volatility may include, among other things:

● potential investigations, proceedings or litigation that involves or affects us;

● risks related to failure to obtain adequate financing on a timely basis and on acceptable terms for our planned expansion;

● actual or anticipated fluctuations in our operating results;

● overall stock market fluctuations;

● our ability to raise capital when we require it, and to raise such capital on favorable terms;

● conditions or trends in the industry;

● changes in market valuations of other similar companies;

● announcements by us or our competitors of expansion of clinics;

● future sales of common stock;

● actions initiated by the SEC or other regulatory bodies;

● departure of key personnel or failure to hire key personnel; and

● general market conditions.

11 Table of Contents

Any of these factors could have a significant and adverse impact on the market price of our common stock. In addition, the stock market in general has at times experienced extreme volatility and rapid decline that has often been unrelated or disproportionate to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock, regardless of our actual operating performance.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.

The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

Even if there is no immediate need for capital, we may choose to issue debt or shares of our common stock in the future and such issuances, if any, could have a dilutive effect on your investment.

We may choose to issue debt or shares of our common stock for investment, acquisition or other business purposes. Even if there is not an immediate need for capital, we may choose to issue securities to sell in public or private equity markets if and when conditions are favorable. Raising funds by issuing securities would dilute the ownership interests of our existing stockholders. Additionally, certain types of equity securities we may issue in the future could have rights, preferences or privileges senior to the rights of existing holders of our common stock.

We cannot assure you that we will declare dividends or have the available cash to make dividend payments, and as a result you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.

Although we do not currently intend to pay dividends, to the extent we decide in the future to pay dividends on our common stock, we will pay such dividends at such times and in such amounts as the board of directors determines appropriate and in accordance with applicable law. Our board of directors may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions and implications on the payment of dividends by us to our stockholders or by our subsidiaries to us and such other factors as our board of directors may deem relevant. There can be no assurance that we will pay dividends going forward or as to the amount of such dividends. As a result, you may not receive any return on an investment in our common stock unless you sell our common stock for a price greater than that which you paid for it.

We are a holding company that depends on cash flow from our wholly owned subsidiary to meet our obligations, and any inability of our subsidiary to pay us dividends or make other payments to us when needed could disrupt or have a negative impact on our business.

We are a holding company with no business operations of our own. Our only significant assets are the outstanding capital stock of our subsidiary, Smile Central, which will conduct all of our operations and own all of our operating assets. Accordingly, our ability to pay our obligations is dependent upon dividends and other distributions from our subsidiary to us. The ability of our subsidiary to pay dividends or make other payments or distributions to us will depend on its respective operating results, and the terms of our current and future financing agreements, which may preclude dividends, distributions or other payments.

12 Table of Contents

In addition, because we are a holding company, claims of our security holders will be structurally subordinated to all existing and future liabilities and obligations (whether or not for borrowed money) of our subsidiary. Therefore, in the event of our bankruptcy, liquidation or reorganization, our assets and those of our subsidiary will be able to satisfy the claims of our security holders only after all of our and our subsidiary’s liabilities and obligations have been paid in full.

Anti-takeover provisions under Nevada law could discourage, delay or prevent a change in control of the Company and may affect the trading price of our common stock.

We are a Nevada corporation and the anti-takeover provisions of the Nevada Revised Statutes may discourage, delay or prevent a third party from acquiring our company, even if doing so may be beneficial to our stockholders. In addition, these provisions could limit the price investors would be willing to pay in the future for shares of our common stock.

Our common stock is and will be subordinate to all of our existing and future indebtedness.

Shares of our common stock are common equity interests in us and, as such, will rank junior to all of our existing and future indebtedness and other liabilities. Additionally, our right to participate in a distribution of assets upon any of our subsidiaries’ liquidation or reorganization is subject to the prior claims of that subsidiary’s creditors.

The Financial Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit your ability to buy and sell our common stock, which could depress the price of our shares.

FINRA has adopted rules that require broker-dealers to have reasonable grounds for believing that an investment is suitable for a customer before recommending that investment to the customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status and investment objectives, among other things. Under interpretations of these rules, FINRA believes that there is a high probability such speculative low-priced securities will not be suitable for at least some customers. Thus, FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our shares, have an adverse effect on the market for our shares, and thereby depress our share price.

RISKS RELATED TO AN EMERGING GROWTH COMPANY

We will face new challenges, increased costs and administrative responsibilities as a public company, particularly after we are no longer an “emerging growth company.”

As a publicly traded company with listed equity securities, we will need to comply with certain laws, regulations and requirements, including certain provisions of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, certain regulations of the Securities and Exchange Commission, or SEC, and certain of the OTCQB listing rules applicable to public companies. Complying with these statutes, regulations and requirements will occupy a significant amount of the time of our board of directors and management and will significantly increase our costs and expenses.

13 Table of Contents

We will need to:

institute a more comprehensive compliance framework;

update, evaluate and maintain a system of internal controls over financial reporting in compliance with the requirements of Section 404 of Sarbanes-Oxley and the related rules and regulations of the SEC;

prepare and distribute periodic public reports in compliance with our obligations under the federal securities laws;

revise our existing internal policies, such as those relating to disclosure controls and procedures and insider trading;

comply with SEC rules and guidelines including a requirement to provide our consolidated financial statements in interactive data format using eXtensible Business Reporting Language;

involve and retain to a greater degree outside counsel and accountants in the above activities; and

enhance our investor relations function.

However, for as long as we are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we are permitted to, and intend to, take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. We will remain an emerging growth company for up to five years, although we would cease to be an emerging growth company as of December 31 of a particular year (i) if we had gross revenue of $1 billion or more in such year, (ii) if the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 in such year, (iii) if at any point in such year, we would have issued more than $1 billion of non-convertible debt during the three-year period prior thereto or (iv) on the date on which we are deemed a “large accelerated issuer” as defined under the federal securities laws. For so long as we remain an emerging growth company, we will not be required to:

have an auditor report on our internal control over financial reporting pursuant to Section 404(b) of Sarbanes-Oxley;

comply with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis);

submit certain executive compensation matters to shareholder advisory votes pursuant to the “say on frequency” and “say on pay” provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the “say on golden parachute” provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010; and

include detailed compensation discussion and analysis in our filings under the Securities Exchange Act of 1934, as amended, or Exchange Act, and instead may provide a reduced level of disclosure concerning executive compensation.

Although we intend to rely on the exemptions provided in the JOBS Act, the exact implications of the JOBS Act for us are still subject to interpretations and guidance by the SEC and other regulatory agencies. In addition, as our business grows, we may no longer satisfy the conditions of an emerging growth company. We are currently evaluating and monitoring developments with respect to these new rules, and we cannot assure you that we will be able to take advantage of all of the benefits from the JOBS Act. In addition, we also expect that being a public company subject to these rules and regulations will make it more expensive for us to maintain adequate director and officer liability insurance. These factors could also make it more difficult for us to attract and retain qualified executive officers and members of our board of directors, particularly to serve on our audit committee.

14 Table of Contents

Failure to establish and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and share price.

As a publicly traded company, we will be required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of Sarbanes-Oxley, which will require, beginning with the filing of our second annual report with the SEC, annual management assessments of the effectiveness of our internal control over financial reporting. However, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. During the course of our testing, we may identify material weaknesses that we may not be able to remediate in time to meet our deadline for compliance with Section 404.

Testing and maintaining internal control can divert our management’s attention from other matters that are important to the operation of our business. We also expect the regulations to increase our legal and financial compliance costs, make it more difficult to attract and retain qualified executive officers and members of our board of directors, particularly to serve on our audit committee, and make some activities more difficult, time-consuming and costly. We may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 and, when applicable to us, our independent registered public accounting firm may not be able or willing to issue an unqualified report on the effectiveness of our internal control over financial reporting. If we conclude that our internal control over financial reporting is not effective, it could have a material adverse effect on our financial condition, results of operations and market for our common stock, and could subject us to regulatory scrutiny.

RISKS RELATED TO OUR ENTERING INTO THE FIELD OF DEVELOPING ULTRASOUND DIAGNOSTICS TOOLS

We have no experience as a company conducting clinical trials.

We have no experience as a company conducting clinical trials and we cannot be certain that any clinical trials we may conduct will be completed on time or at all. Clinical trials require significant financial and management resources, and reliance on third-party clinical investigators, contract research organizations, or CROs, or consultants. Relying on third-party clinical investigators or CROs may force us to encounter delays that are outside of our control.

Clinical trials are expensive, time-consuming and difficult to design and implement.

Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidate is based on new technology, we expect that it will require extensive research and development and have substantial related costs. At this time we anticipate that the cost of required research will be at least $840,000, and the actual costs may be significantly higher. In order to conduct such research and development, we will need to raise additional capital through issuances of equity or debt which we may be unsuccessful in doing or on terms favorable to the Company.

15 Table of Contents

Our product candidate may not achieve commercialization and our commercial opportunity may be limited.

Development and obtaining regulatory approval for and commercializing our product candidate will require substantial additional funding and are prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance our product candidate through the development process.

Even if we receive FDA approval to market our product candidate for the diagnosis of malignancy in a tumor, we cannot assure you that our product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize our product candidate, our commercial opportunity will be limited.

If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidate.

We expect to spend substantial amounts to on the required research and clinical development of our product candidate. If approved, we will require significant additional amounts in order to launch and commercialize our product candidate. At this time we anticipate that the cost of required research will be at least $840,000, and the actual costs may be significantly higher.

We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidate.

Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidate.

We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidate, or grant licenses on terms unfavorable to us.

The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidate.

The regulatory approval pathway for our product candidate may be uncertain, complex, expensive and lengthy, and approval may not be obtained.

16 Table of Contents

We may experience delays in completing planned clinical trials for a variety of reasons, including delays related to:

· the availability of financial resources to commence and complete the planned trial; · reaching agreement on acceptable terms with prospective third parties to assist in the research, the terms of which can be subject to extensive negotiation and may vary significantly; · obtaining approval at each clinical trial site by an independent institutional review board; · recruiting suitable patients to participate in a trial; · having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up; · clinical trial sites deviating from trial protocol or dropping out of a trial; or · adding new clinical trial sites.

A clinical trial may be suspended or terminated by us, the institutional review board for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial, or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidate, the commercial prospects for our product candidate will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.

Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.

The patent we purchased was issued in August 2000 and expires in August 2020

The patent we purchased (Patent Number: 6,112,108) was issued in August 2000 and the patent protection under the patent expires in August 2020, leaving us a short period of time for protection under the patent.

Item 1B. Unresolved Staff Comments.

Not applicable to smaller reporting companies.

17 Table of Contents

Item 2. Description of Property

Clinic	Rental per mth		Tenancy Period
Aljunied	$	7,000	Aug 2014 – Jul 2017
Aljunied – Dental Lab	$	2,000	May 2015 – May 2017
Jurong	$	34,000	Sep 2015 – Sep 2018
Hougang	$	19,916	May 2015 – May 2018
HougangCentral	$	6,500	Apr 2014 – Apr 2016
SCD Centre	$	20,000	Aug 2016 – Aug 2019
Toa Payoh	$	16,000	Apr 2015 – Mar 2018

Item 3. Legal Proceedings

~~None~~From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party and which would reasonably be likely to have a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or a witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.

Item 4. Mine Safety Disclosures

Not applicable.

~~PART~~Our IIcommon stock is not yet quoted on any markets or exchanges.

~~Item~~Our 5shares are issued in registered form. ~~Market~~ClearTrust ~~for~~Stock ~~Common~~Transfer ~~Equity~~Agent., 16540 Pointe Village Drive, Suite 205, Lutz, FL 33558 (Telephone: (813) 235-4490; Facsimile: (813) 388-4549 is the registrar and ~~Related~~transfer ~~Stockholder~~agent ~~Matters~~for our common shares.

~~Market~~On ~~Information~~December 5, 2018, the shareholders’ list showed 33 registered shareholders with 3,6967,000 shares of common stock outstanding.

~~There~~Dividend is currently a very limited public market for our common shares. Our common shares are listed on the OTC Pink Sheets at this time, but there have been no trades. Trading in stocks quoted on the OTC Pink Sheets is often thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company’s operations or business prospects. Policy

~~OTC~~We ~~Pink~~have ~~Sheet~~not ~~securities~~paid ~~are~~any ~~not~~cash ~~listed~~dividends oron ~~traded~~our oncommon ~~the~~stock ~~floor~~and ofhave anno ~~organized~~present ~~national~~intention orof ~~regional~~paying ~~stock~~any ~~exchange.~~dividends ~~Instead,~~on ~~OTC~~the ~~Pink~~shares ~~Sheet~~of ~~securities~~our ~~transactions~~common ~~are~~stock. ~~conducted~~Our ~~through~~current apolicy ~~telephone~~is ~~and~~to ~~computer~~retain ~~network~~earnings, ~~connecting~~if ~~dealers~~any, infor ~~stocks.~~use ~~OTC~~in ~~Pink~~our ~~Sheet~~operations ~~issuers~~and ~~are~~in ~~traditionally~~the ~~smaller~~development ~~companies~~of ~~that~~our dobusiness. ~~not~~Our ~~meet~~future ~~the~~dividend ~~financial~~policy ~~and~~will ~~other~~be ~~listing~~determined ~~requirements~~from oftime ato ~~regional~~time orby ~~national~~our ~~stock~~board ~~exchange~~of directors.

~~Number~~Equity ofCompensation ~~Holders~~Plan Information

AsWe ofdo ~~June12,~~not ~~2017,~~have ~~the~~any ~~3,697,000 issued~~equity ~~and~~compensation ~~outstanding shares of common stock were held by a total of 34 shareholders of record~~plans.

~~Dividends~~Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities

NoWe ~~cash~~did ~~dividends~~not ~~were~~sell ~~paid~~any onequity ~~our~~securities ~~shares~~which ofwere ~~common~~not ~~stock~~registered ~~during~~under the ~~fiscal~~Securities Act during the year ended December 31, ~~2016.~~2017 Wethat ~~have~~were not ~~paid~~otherwise ~~any~~disclosed ~~cash~~on ~~dividends~~our ~~since~~quarterly ~~September~~reports ~~18,~~on ~~2015~~Form ~~(inception)~~10-Q ~~and~~or doour ~~not~~current ~~foresee~~reports ~~declaring~~on ~~any~~Form ~~cash~~8-K ~~dividends~~filed onduring ~~our~~the ~~common~~year ~~stock~~ended inDecember ~~the~~31, ~~foreseeable future~~2017.

~~Recent~~Purchase ~~Sales~~ of ~~Unregistered~~Equity Securities by the Issuer and Affiliated Purchasers

~~The~~We ~~Company~~did ~~has~~not ~~500,000,000,~~purchase ~~$0.001~~any ~~par~~of ~~value~~our shares of common stock ~~authorized~~or other securities during our fourth quarter of our fiscal year ended December 31, 2017.

On6 ~~September~~Table ~~19, 2015 we entered into a Share Exchange Agreement with the three (3) owners~~ of Smile Central Dental Group, whereby we agreed to issue 3 million shares of common stock in exchange for all of the issued and outstanding shares of capital stock of Smile Central Dental Group. The three (3) owners of Smile Central Dental Group as a result became the executive officers and directors of Medico International.Contents

19 Table of Contents

Medico International issued the securities to three (3) non-U.S. persons (as that term is defined in Regulation S of the Securities Act of 1933, as amended) in an offshore transaction in which we relied on the registration exemption provided for in Regulation S and/or Section 4(2) of the Securities Act of 1933, as amended (the “Act”), as the conditions of Regulation S were met, including but not limited to the following conditions:

· Each of the parties receiving shares are residents and citizens of Singapore and were in Singapore at the time of the sale of the shares;

· Each of the parties receiving shares agree to resell the shares only in accordance with Regulation S, pursuant to a registration under the Act, or pursuant to an available exemption from registration; and

· The certificate representing the shares sold contain a legend that transfer of the shares is prohibited except in accordance with the provisions of Regulation S, pursuant to a registration under the Act, or pursuant to an available exemption from registration and the hold may engage in hedging transactions with regards to Medico’s common stock unless in compliance with the Act.

As of June 12, 2017, the 3,697,000 issued and outstanding shares of common stock were held by a total of 34 shareholders of record.

Item 6. Selected Financial Data

~~Not~~As ~~applicable~~a to “smaller reporting ~~companies~~company”, we are not required to provide the information required by this Item.

Item 7. Management'’s Discussion and Analysis of Financial Condition and Results of Operations

~~FORWARD~~The ~~LOOKING~~following ~~STATEMENTS~~discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this Annual Report. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

~~Statements~~Results ~~made in this Form 10-K that are not historical or current facts are "forward-looking statements". These statements often can be identified by the use~~ of ~~terms~~Operations ~~such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We wish to caution readers not to place undue reliance on any such forward~~-~~looking~~ ~~statements,~~Years ~~which~~Ended ~~speak~~December ~~only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However~~31, ~~forward-looking~~2017 ~~statements are subject to risks, uncertainties~~ and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.2016

~~OVERVIEW~~The following summary of our results of operations should be read in conjunction with our financial statements for the years ended December 31, 2017 and 2016, which are included herein.

WeYears ~~are~~ended aDecember ~~newly formed Nevada corporation organized for the purposes of acting as the holding company for Smile More Holdings Pte. Ltd.~~31, ~~which~~2017 ~~is a Singapore corporation that owns~~ and ~~operates~~December ~~dental~~31, clinics in Singapore under the Smile Central name (referred to herein as “Smile Central”). Smile Central is a dental company employing the latest techniques in oral care and oral surgery in Singapore. Smile Central operates out of 5 locations in population-dense high foot traffic residential centers all over Singapore.2016

20For ~~Table~~the ofyear ~~Contents~~ended December 31, 2017 and 2016, we did not earn any revenue.

~~Smile~~Operating ~~Central’s~~expenses ~~business~~were ~~model focuses on recruiting qualified and experienced dentists~~$41,016 ~~supported~~for ~~by well-trained clinic support staff. Our dentists have post-graduate training in~~ the ~~fields~~year ofended ~~endodontics,~~December ~~orthodontics~~31, ~~periodontics~~2017, ~~prosthodontics,~~compared ~~paedodontics~~to $100,828 ~~oral~~for ~~surgery~~the ~~and~~year ~~implant~~ended ~~dentistry.~~December ~~Hence~~31, we2016. ~~are~~The ~~able~~decrease toin ~~carry~~operating ~~out~~expense ~~procedures~~is ~~ranging~~primarily ~~from~~due ~~the routine cleaning and filling~~ to ~~the~~a ~~most~~decrease ~~complex~~in ~~ones~~professional ~~involving aesthetics and surgery~~fees.

~~Years~~For the years ended December 31, 2017, we had other income of $5,142, compared to $0 in other income during the year ended December 31, 2016. ~~and~~The increase in other income was attributed to a gain on forgiveness of accounts payable for the year ended December 31, ~~2015~~2017, that did not occur in the year ended December 31, 2016.

~~For~~On ~~the~~June ~~year ended December 31~~5, ~~2016 we earned Dental Service Revenue of $6~~2017,~~543,428~~ ~~compared~~the toCompany ~~Dental~~sold ~~Service~~all ~~Revenue~~ of ~~$4,905,241 for~~ the ~~year~~issued ~~ended~~and ~~December~~outstanding ~~31,~~ordinary ~~2015.~~shares ~~Cost~~ of ~~Services for~~ the ~~year~~Company’s ~~ended~~100% ~~December~~wholly-owned 31subsidiary, ~~2016~~Smile ~~were~~More ~~$5,673,813~~Holdings ~~resulting~~Pte. inLtd., a ~~Gross~~Singaporean ~~Profit~~corporation. ofDuring ~~$869,615,~~the ~~compared to Cost of Services for~~ year ended December 31, ~~2015 of $3~~2017,~~781,246~~ ~~resulting~~loss infrom adiscontinued ~~gross~~operations ~~profit~~was of $1133,~~123~~241,~~995.~~ ~~Dental~~compared ~~service~~to ~~revenue for the year ended December 31, 2016 increased by~~ $1819,~~638,187~~182 ~~over~~for the year ended December 31, ~~2015 due to additional clinics, increased activity, patient treatments and patients~~2016.

~~Operating~~The ~~expenses~~decrease ~~were~~in ~~$1,884,053~~loss ~~for~~from ~~the~~discontinued ~~year~~operations ~~ended~~is ~~December~~primarily ~~31, 2016, compared to $1,356,764 for the year ended December 31, 2015,~~ due to ~~additional~~decreased ~~clinics,~~operating ~~increased operations, patient treatments, professional fees and resulting overhead. Operating~~ expenses for the year ended December 31, 2016 were comprised of $845,684 for rental, $384,287 for general and administrative expenses, $299,956 for professional fees, $236,711 for depreciation, and $117,415 for staff costs, compared to $561,167 for rental, $158,781 for general and administrative expenses, $408,413 for professional fees, $139,930 for depreciation, and $88,473 for staff costs for the year ended December 31, 2015.

~~For~~Liquidity ~~the year ended December 31, 2016, we had other income of $102,832~~ and ~~interest~~Capital expense of $8,404, compared to $149,894 in other income and $5,833 in interest expense during the year ended December 31, 2015. The decrease in other income was attributed to a gain on forgiveness of debt for the year ending December 31, 2015, that did not re-occur in the year ended December 31, 2016.Resources

~~LIQUIDITY~~As ~~AND~~at ~~CAPITAL~~December ~~RESOURCES~~31, 2017 our company’s cash balance was $0 and total assets were $0. As at December 31, 2016, our Company’s cash balance was $0 and total assets were $2,077,381. The decrease in total assets is due to sales of investment in subsidiaries.

~~Years~~As ~~ended~~at December 31, ~~2016~~2017, ~~and~~our company had total liabilities of $459,694, compared with total liabilities of $2,337,165 as at December 31, ~~2015~~2016. The decrease in total liabilities is due to sales of investment in subsidiaries.

~~Cash~~As ~~Flows~~ at December 31, 2017, our company had working capital deficiency of $459,694 compared with working capital deficiency of $259,784 as at December 31, 2016. The increase in working capital deficiency was primarily attributed to the decrease in assets from discontinued operations and liabilities from discontinued operations.

~~Our~~7 ~~primary~~Table ~~liquidity and capital requirements are for cost~~ of ~~services and administrative expenses. We fund our operations with cash generated from dental service revenue, capital contributions, and issuances of common stock.~~Contents

~~Operating~~Cash ~~Activities~~Flows

~~For~~Our ~~the year~~primary ~~ended~~liquidity ~~December~~and ~~31,~~capital ~~2016,~~requirements ~~net~~are ~~cash~~for ~~used~~cost inof ~~operating~~services ~~activities~~and ~~was~~administrative ~~$228,287~~expenses. ~~This~~In ~~negative~~the ~~cash~~past ~~flow~~we ~~related~~fund to our ~~net loss~~operations ofwith ~~$920,010,~~cash ~~adjusted~~generated ~~for~~from ~~depreciation~~dental ofservice ~~$575~~revenue,~~689,~~ ancapital ~~increase in loss on disposal of equipment of $18~~contributions,~~967,~~ ~~an increase in accounts receivable of $152,841, a decrease in other receivables of $69,000, an increase in prepaid expenses~~ and ~~deposits~~issuances of ~~$28,361,~~common anstock. ~~increase~~Going inforward ~~inventory~~the ofCompany ~~$29,062,~~will annot ~~increase~~generate inany ~~accounts~~cash ~~payable~~from ofdental ~~$163,174,~~service ~~an increase in accrued and other payables of $72,703, and an increase in deferred~~ revenue ~~of $2,454~~.

~~This~~Cash ~~compared~~Flow tofrom ~~net~~Operating ~~cash provided by operating activities during the year ended December 31, 2015 in the amount of $272,313.~~Activities

21During ~~Table~~the ofyear ~~Contents~~ended December 31, 2017, our company generated $304,115 in cash from operating activities, compared to $1,073,894 cash used in operating activities during the year ended December 31, 2016. The increase in cash provided from operating activities for the year ended December 31, 2017 was attributed to a change in assets and liabilities from discontinued operations.

~~The~~Cash ~~Company’s~~Flow ~~consolidated~~from ~~financial~~Investing statements accompanying this report have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. As of December 31, 2016, the Company has accumulated deficit of $1,161,700 since inception and has a working capital deficiency of $1,120,357.Activities

~~Management's~~During ~~plans include raising capital through~~ the ~~equity~~year ~~markets~~ended toDecember ~~fund operations and eventually~~31, ~~generating~~2017 ~~profit~~our ~~through~~company ~~its~~used ~~business; however~~$359,066 ~~there~~for ~~can~~sales beof noinvestment ~~assurance~~in ~~that~~subsidiaries ~~the Company will be successful~~ in ~~such~~investing activities. ~~The~~compared ~~consolidated financial statements accompanying this report do not include any adjustments relating~~ to ~~the~~$0 ~~recovery~~used ofin ~~the~~investing ~~recorded~~activities ~~assets~~during or the ~~classifications~~year ofended ~~the~~December ~~liabilities~~31, ~~that might be necessary should the Company be unable to continue as a going concern~~2016.

~~Investing~~Cash Flow from Financing Activities

~~For~~During the year ended December 31, ~~2016,~~2017 ~~net~~our ~~cash~~company ~~used~~received in$17,865 ~~investing~~from financing activities ~~was~~compared to $~~438~~1,~~226~~056,473 ~~compared~~received tofrom ~~net~~financing ~~cash~~activities ~~of $361,286 used~~ during the year ended December 31, ~~2015~~2016. The cash ~~used~~flow for ~~both~~financing ~~periods~~activities ~~was~~for ~~primarily driven by~~ the ~~cost~~year ofended ~~building~~December ~~and~~31, ~~opening~~2017, was a ~~total~~result of ~~four~~ ~~(4)~~loans ~~dental~~from ~~clinics~~related inparties ~~Singapore~~of ~~during those periods~~$17,865. ~~which~~The ~~resulted~~cash inflow anfor ~~increase~~financing inactivities for the ~~purchase~~year ofended ~~property~~December 31, ~~plant~~2016, ~~and~~was ~~equipment~~a ~~for~~result ~~the~~of ~~year~~issuance ~~ended~~of ~~December~~shares 31of $697,000 ~~2016~~and loans from related parties of $359,473.

~~Financing~~Limited ~~Activities~~Operating History; Need for Additional Capital

~~Net~~There ~~cash~~is ~~provided~~no byhistorical ~~financing~~financial ~~activities~~information ~~was~~about ~~$620,243~~us ~~for~~on ~~the year~~which ~~ended~~to ~~December~~base ~~31,~~an ~~2016.~~evaluation ~~This~~of ~~was~~our ~~the~~performance. ~~result~~We ~~of issuance~~have ofgenerated ~~shares~~no ~~for~~revenues afrom ~~total~~operations. ofWe ~~$697,000,~~cannot ~~loans~~guarantee ~~from~~we ~~related~~will ~~parties~~be successful in ~~the~~our ~~amount~~business ofoperations. ~~$147,020,~~Our ~~partially~~business ~~offset~~is bysubject ~~the~~to ~~repayment~~risks ofinherent ~~capital lease obligations~~ in the ~~amount~~establishment of ~~$223~~a new business enterprise,~~777,~~ ~~loans~~including ~~from~~limited ~~related~~capital ~~parties~~resources, inpossible ~~the~~delays ~~amount~~in ofdeveloping ~~$581~~our website,~~503~~ and ~~the~~possible ~~repayment~~cost ofoverruns ~~capital~~due ~~lease~~to ~~obligations in~~ the ~~amount~~price ofand ~~$294,502,~~cost ~~during~~increases ~~the~~in ~~year~~supplies ~~ended~~and ~~December 31, 2015~~services.

~~PLAN~~At OFpresent, ~~OPERATION~~we do not have enough cash on hand to cover operating costs for the next 12 months.

~~For~~If ~~the period from inception (January 20, 2014) through December 31, 2014,~~ we ~~incurred~~are aunable ~~net~~to ~~loss~~meet ofour ~~$152,982~~needs ~~and total~~for ~~comprehensive~~cash ~~loss~~from ofeither ~~$146,584.~~our ~~However~~operations, ~~during~~or ~~the~~possible ~~year~~alternative ~~ended December 31~~sources, ~~2015,~~then we ~~incurred~~may abe ~~net~~unable ~~loss~~to ofcontinue, ~~$88~~develop,~~708~~ ~~and~~or ~~total~~expand ~~comprehensive~~our ~~loss of $81,732~~operations.

~~Subsequent~~We have no plans to ~~December~~undertake ~~31,~~any ~~2015,~~product research and development during the ~~Company~~next ~~raised~~twelve ~~$697,000~~months. ~~from~~There ~~its~~are ~~public~~also ~~offering~~no ofplans ~~stock.~~or ~~The~~expectations ~~Company~~to ~~will~~acquire ~~use~~any ~~such~~plant ~~funds~~or ~~for~~plant equipment in the ~~building~~first year of ~~additional clinics~~operations.

~~Recent~~Liquidity ~~Developments~~and Capital Resources

~~Due~~As toof ~~the~~December ~~continued~~31, ~~consolidated~~2017, ~~losses~~we ~~experienced~~had byno ~~the~~cash. ~~Company~~As asof ~~the~~December ~~result~~31, of2017, ~~the~~our ~~losses~~current ofliabilities ~~the~~and ~~Company~~stockholders’s ~~wholly-owned~~deficit ~~subsidiary,~~was ~~Smile More Holdings Pte~~$459,694. ~~Ltd.,~~We ado ~~Singaporean~~not ~~corporation~~have ~~(“Smile~~sufficient ~~Central”),~~funds ~~which~~to ~~included~~operate ~~$232,769~~ for the ~~fiscal~~next ~~year~~twelve ~~ended~~months. ~~December~~We ~~31,~~have ~~2015,~~to ~~$801,760~~issue ~~for~~debt ~~the~~or ~~fiscal~~equity ~~year~~or ~~ended~~enter ~~December~~into ~~31,~~a ~~2106,~~strategic ~~the~~arrangement ~~Board~~with ofa ~~Directors~~third ofparty ~~the~~in ~~Company~~order ~~believed~~to itfinance ~~was~~our inoperations. ~~the~~There ~~best~~can ~~interests~~be ofno ~~the~~assurance ~~Company~~that ~~and~~additional ~~its~~capital ~~shareholders~~will be available to ~~dispose~~us. ofWe ~~Smile~~currently ~~Central.~~have Inno ~~addition~~agreements, ~~the~~arrangements ~~Company~~or ~~had~~understandings ~~provided~~with ~~Smile~~any ~~Central~~person ~~with~~to ~~over~~obtain ~~$600,000~~funds inthrough ~~intra-company~~bank loans, ~~(the~~lines ~~“Intra-Company~~of ~~Loan”).~~credit or any other sources.

~~The~~8 ~~Company’s~~Table ~~former majority shareholders, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. (the “Majority Shareholders”), became shareholders~~ of the Company in 2015 by exchanging all of the outstanding share capital of Smile Central (“Smile Shares”) for 3,000,000 shares of the Company’s common stock (the “Medico Shares”) and the Majority Shareholders desired to re-acquire the Smile Shares. Contents

OnContractual June 5, 2017, the Company closed the transactions under the Share Exchange Agreement (“ Share Exchange Agreement”) by and between the Company, Eminent Healthcare Pte. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited company, for the sale of all of the issued and outstanding ordinary shares of the Company’s 100% wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (the “Stock Purchase”). Prior to the closing of the Stock Purchase, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. were the Company’s majority shareholders. Liew Min Hin, the Company’s former Chief Financial Officer and former member of the Board of Directors, owns 100% of Eminent Healthcare Pte. Ltd., and is the father of Dr. Daniel Liew, the Company’s former Chief Executive Officer and former member of the Board of Directors.Obligations

22As ~~Table~~a of“smaller ~~Contents~~reporting company”, we are not required to provide tabular disclosure obligations.

~~Pursuant~~Going to the Share Exchange Agreement, in consideration for transferring the Smile Shares to the Majority Shareholders and waiving the Intra-Company Loan, the Company received all of the rights, interests, claim and title in that certain US patent known as “Method for diagnosing malignancy in pelvic tumors”, US Patent No. 6,112,108 (the “Patent”), which Targeted Solutions Global Limited, a United Kingdom Private limited company (“TSG”) had the right and ability to deliver to the Company and in connection with the closing of the Share Exchange Agreement, Jiang Chun Yan was appointed as the CEO and sole member of the Company’s Board of Directors. Concern

InAs ~~addition~~of December 31, ~~under~~2017, our company had a net loss of $169,115 and has earned no revenues. Our company intends to fund operations through equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital and other cash requirements for the ~~Share~~year ~~Exchange~~ending ~~Agreement~~December 31, ~~TSG~~2019. ~~received~~The ability of our company to emerge from the ~~Majority~~development ~~Shareholders~~stage ~~the~~is ~~Medico~~dependent ~~Shares~~upon, among other things, obtaining additional financing to continue operations, and ~~the~~development ~~Majority~~of ~~Shareholders~~our ~~received~~business ~~$200~~plan. In response to these problems,~~000~~ ~~from~~management ~~TSG~~intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about our company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~The~~Off-Balance ~~effect~~Sheet of the transactions set forth in the Share Exchange Agreement is that commencing June 5, 2017 the Company will no longer own and operate dental clinics in Singapore but will focus its efforts in the area of cancer diagnostics tools in connection with the Patent.Arrangements

~~Recent~~We ~~Developments~~have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

OnCritical ~~March~~Accounting 7,Policies 2017, the Company filed a Schedule 14C Information statement with the Securities and Exchange Commission in connection with the following action taken pursuant to the written consent of the shareholders holding a majority of the voting power of the Company’s issued and outstanding capital stock, dated as of February 28, 2017 (the “Written Consent”) authorizing the following:

~~Entry~~We ~~into~~prepare aour ~~Stock~~financial ~~Purchase~~statements ~~Agreement~~in ~~dated~~conformity ~~February~~with 28GAAP, ~~2017~~which ~~(“Stock~~requires ~~Purchase~~management ~~Agreement”),~~to ~~with~~make ~~Dr.~~certain ~~Daniel~~estimates ~~Liew,~~and ~~the~~apply ~~Company’s~~judgments. ~~Chief~~We ~~Executive~~base ~~Office~~our estimates and ajudgments ~~member~~on ofhistorical ~~the~~experience, ~~Company’s~~current ~~Board~~trends ofand ~~Directors,~~other ~~for~~factors ~~the~~that ~~sale~~management ofbelieves ~~all~~to ofbe ~~the~~important ~~issued~~at ~~and~~the ~~outstanding~~time ~~ordinary~~the ~~shares~~financial ofstatements ~~the~~are ~~Company’s~~prepared. ~~100%~~On ~~wholly-owned~~a ~~subsidiary~~regular basis, ~~Smile~~we ~~More~~review ~~Holdings~~our ~~Pte.~~accounting ~~Ltd.,~~policies aand ~~Singaporean~~how ~~corporation~~they ~~(the~~are ~~“Stock~~applied ~~Purchase”).~~and disclosed in our financial statements.

~~The~~While ~~effect~~we ofbelieve ~~the transactions set forth in the Stock Purchase Agreement is~~ that the ~~Company~~historical ~~will~~experience, nocurrent ~~longer~~trends ~~own~~ and ~~operate~~other ~~dental~~factors ~~clinics~~considered insupport ~~Singapore and will focus its efforts in~~ the ~~area~~preparation of ~~cancer~~our ~~diagnostics~~financial ~~tools.~~statements ~~The Company has purchased an ultrasound patent from Ramot University for Applied Research & Industrial Development Ltd.~~ in ~~Israel~~conformity ~~and~~with ~~is planning to develop the technology to diagnose malignancies in pelvic tumors. The company has also engaged Dr. Ron Tepper (phd)~~GAAP, ~~one~~actual ofresults ~~the~~could ~~investors~~differ offrom ~~this~~our ~~patent,~~estimates ~~to help the company develop~~ and ~~bring~~such ~~the~~differences ~~ultrasound~~could ~~diagnostics~~be ~~tools to market~~material.

~~OFF-BALANCE~~Recent ~~SHEET~~Accounting ~~ARRANGEMENTS~~Pronouncements

WeManagement ~~did~~has ~~not~~considered ~~have~~all ~~during~~recent accounting pronouncements issued since the ~~periods~~last ~~presented,~~audit ~~and~~of weour dofinancial ~~not~~statements. ~~currently~~The ~~have,~~Company’s ~~any~~management ~~off-balance~~believes ~~sheet~~that ~~arrangements,~~these asrecent ~~defined~~pronouncements inwill ~~the~~not ~~rules~~have ofa ~~the~~material ~~Securities~~effect ~~Exchange~~on ~~Commission~~our company’s financial statements.

Item 7A. Quantitative and Qualitative Disclosures ~~about~~About Market Risk

~~The~~As ~~Company~~a ~~does~~“smaller ~~not~~reporting ~~hold~~company”, ~~any~~we ~~assets~~are ornot ~~liabilities~~required ~~requiring~~to ~~disclosure~~provide ~~under~~the information required by this ~~item~~Item.

239 Table of Contents

Item 8. Financial Statements and Supplementary Data

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Medico International, Inc.

WeOpinion ~~have~~on ~~audited~~ the ~~accompanying~~Financial consolidated balance sheets of Medico International Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for the years then ended. Medico International Inc.’s management is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.Statements

We ~~conducted~~have ~~our~~audited ~~audits~~the inaccompanying ~~accordance~~consolidated ~~with~~balance ~~the~~sheets ~~standards~~ of ~~the~~Medico ~~Public~~International, ~~Company~~Inc. ~~Accounting Oversight Board~~ (~~United~~the ~~States~~Company). ~~Those~~as ~~standards~~of ~~require~~December ~~that~~31, we2017 ~~plan~~ and ~~perform~~2016, ~~the~~and ~~audit to obtain reasonable assurance about whether~~ the ~~financial~~related statements ~~are free~~ of ~~material~~operations ~~misstatement.~~and ~~The~~comprehensive ~~Company is not required to have~~loss, ~~nor~~stockholders’ ~~were we engaged to perform~~deficit, anand ~~audit~~cash offlows ~~its~~for ~~internal~~each ~~control over financial reporting. Our audit included consideration~~ of ~~internal~~the ~~control~~years ~~over~~in ~~financial~~the ~~reporting~~two-year asperiod aended ~~basis~~December ~~for~~31, ~~designing~~2017, ~~audit~~and ~~procedures~~the ~~that~~related ~~are~~notes ~~appropriate~~(collectively inreferred ~~the~~to ~~circumstances,~~as ~~but not for~~ the ~~purpose~~financial ofstatements). ~~expressing~~In anour opinion, on the ~~effectiveness~~financial ofstatements ~~the~~present ~~company’s~~fairly, ~~internal~~in ~~control~~all ~~over~~material ~~financial reporting. Accordingly~~respects, wethe ~~express~~financial noposition ~~such~~of ~~opinion.~~the AnCompany ~~audit~~as ~~also~~of ~~includes~~December ~~examining~~31, on2017 aand ~~test basis~~2016, ~~evidence supporting the amounts~~ and ~~disclosures in~~ the ~~financial~~results ~~statements,~~of ~~assessing~~its ~~the~~operations ~~accounting~~and ~~principles~~its ~~used~~cash ~~and~~flows ~~significant~~for ~~estimates~~each ~~made~~of bythe ~~management,~~years asin ~~well~~the astwo-year ~~evaluating~~period ~~the~~ended ~~overall~~December ~~financial~~31, ~~statement~~2017, ~~presentation.~~in Weconformity ~~believe~~with ~~that~~accounting ~~our~~principles ~~audits~~generally ~~provide~~accepted ain ~~reasonable~~the ~~basis~~United ~~for~~States ~~our~~of ~~opinion~~America.

InBasis our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Medico International Inc. as of December 31, 2016 and 2015, and the results of its operations and its cash flows for ~~the years then ended, in conformity with accounting principles generally accepted in the United States of America.~~Opinion

~~The~~These ~~accompanying consolidated~~ financial statements ~~have~~are ~~been~~the ~~prepared~~responsibility ~~assuming~~of ~~that~~the Company’s management. Our responsibility is to express an opinion on the Company’s ~~will~~financial ~~continue~~statements asbased aon ~~going~~our ~~concern~~audits. AsWe ~~discussed~~are ina ~~Note~~public 3,accounting firm registered with the Public Company ~~has~~Accounting ~~incurred~~Oversight ~~net~~Board ~~losses~~(United States) (PCAOB) and ~~negative~~are ~~working~~required ~~capital~~to ~~since~~be ~~inception.~~independent ~~These~~with ~~factors,~~respect ~~and~~to the ~~need~~Company ~~for additional financing~~ in ~~order~~accordance ~~for~~with the ~~Company~~U.S. tofederal ~~meet~~securities ~~its~~laws ~~business~~and ~~plans,~~the ~~raise~~applicable ~~substantial~~rules ~~doubt~~and ~~about~~regulations of the ~~Company’s~~Securities ~~ability~~and toExchange ~~continue~~Commission asand athe ~~going concern~~PCAOB.

~~/s/~~We ~~Accell~~conducted ~~Audit~~our &audits ~~Compliance~~in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, Pwhether due to error or fraud.A The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. ~~Tampa~~As part of our audits, ~~Florida~~we ~~June~~are 16required to obtain an understanding of internal control over financial reporting, ~~2017~~but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company has incurred net losses and negative cash flow from operations since inception. These factors, and the need for additional financing in order for the Company to meet its business plans raises substantial doubt about the Company’s ability to continue as a going concern. Our opinion is not modified with respect to that matter.

/s/ Accell Audit & Compliance, P.A.

We have served as the Company’s auditor since 2014.

Tampa, Florida

January 14, 2019

4806 West Gandy Boulevard · Tampa, Florida 33611 · 813.440.6380

~~24 Table of Contents~~10

Medico International Inc.

Consolidated Financial Statements

As of and For the Years Ended December 31, 2016 and 2015

MEDICO INTERNATIONAL INC.

CONSOLIDATED BALANCE SHEETS

	December 31,2016			December 31,2015
	December 31,
	2017			2016
ASSETS
Current Assets
Cash and cash equivalents	$	287,754		$	316,603
Prepaid expenses and deposits	$	-		$	250
Accounts receivable		416,658			263,817
Assets from discontinued operations		-			2,077,131
Other receivables		-			69,000
Total Current Assets		-			2,077,381
Prepaid expenses and deposits		222,084			193,723
TOTAL ASSETS	$	-		$	2,077,381
Inventory		113,229			84,167
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Total Current Assets		1,039,725			927,310
Property and equipment, net		1,037,656			993,968
TOTAL ASSETS	$	2,077,381		$	1,921,278
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable	$	~~633~~34,~~247~~882		$	~~470~~17,~~073~~123
Accrued and other payables		186,894			114,191
Due to related parties		424,812			406,947
Due to related parties		1,150,316			1,003,296
Liabilities from discontinued operations		-			1,913,095
Deferred revenue		2,454			-
Total Current Liabilities		459,694			2,337,165
Capital lease obligations - current		187,171			212,570
TOTAL LIABILITIES		459,694			2,337,165
Total Current Liabilities		2,160,082			1,800,130
Commitments and Contingencies (Note 8)
Capital lease obligations		177,083			175,343
TOTAL LIABILITIES		2,337,165			1,975,473
COMMITMENTS AND CONTINGENCIES (NOTE 9)
STOCKHOLDERS’ DEFICIT
Common stock, $0.001 par value; 500,000,000 shares authorized, 3,697,000 and 3,000,000 shares issued and outstanding, respectively		3,697			3,000
Common stock, $0.001 par value; 500,000,000 shares authorized, 3,697,000 shares issued and outstanding		3,697			3,697
Additional paid-in capital		867,424			~~171~~867,~~121~~424
Accumulated deficit		(1,~~161~~330,~~700~~815	)		(~~241~~1,~~690~~161,700	)
Accumulated other comprehensive gain		~~30,795~~-			1330,~~374~~795
TOTAL STOCKHOLDERS' DEFICIT		(259,784	)		(54,195	)
TOTAL STOCKHOLDERS’ DEFICIT		(459,694	)		(259,784	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	2,077,381		$	1,921,278
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	-		$	2,077,381

See the notes to the consolidated financial statements

2511 Table of Contents

MEDICO INTERNATIONAL INC.~~CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS~~

	Year Ended			Year Ended
	December 31,			December 31,
	2016			2015
DENTAL SERVICE REVENUE, NET	$	6,543,428		$	4,905,241
COST OF SERVICES		5,673,813			3,781,246
GROSS PROFIT		869,615			1,123,995
OPERATING EXPENSES
Rental		845,684			561,167
General and administrative		384,287			158,781
Professional fees		299,956			408,413
Depreciation		236,711			139,930
Staff costs		117,415			88,473
Total Operating Expenses		1,884,053			1,356,764
LOSS FROM OPERATIONS		(1,014,438	)		(232,769	)
OTHER INCOME/(EXPENSE)
Other income		102,832			149,894
Interest expense		(8,404	)		(5,833	)
		94,428			144,061
LOSS BEFORE INCOME TAXES		(920,010	)		(88,708	)
Provision for income taxes		-			-
NET LOSS	$	(920,010	)	$	(88,708	)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments		17,421			6,976
TOTAL COMPREHENSIVE LOSS	$	(902,589	)	$	(81,732	)
Basic and Diluted Loss per Common Share	$	0.25		$	(0.06	)
Basic and Diluted Weighted Average Common Shares Outstanding		3,647,486			1,495,371

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Year ended December 31,
	2017			2016

REVENUE	$	-		$	-

OPERATING EXPENSES
General and administrative		3,925			537
Professional fees		37,091			100,291
Total Operating Expenses		41,016			100,828

LOSS FROM OPERATIONS		(41,016	)		(100,828	)

OTHER INCOME/(EXPENSES)
Forgiveness of accounts payable		5,142			-
		5,142			-

LOSS BEFORE INCOME TAXES		(35,874	)		(100,828	)
Provision for income taxes		-			-
LOSS FROM CONTINUING OPERATION		(35,874	)		(100,828	)

DISCONTINUED OPERATIONS
Loss from discontinued operations		(55,803	)		(819,182	)
Loss on disposal of subsidiaries		(77,438	)		-
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX BENEFITS		(133,241	)		(819,182	)

NET LOSS	$	(169,115	)	$	(920,010	)

OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments		37,086			17,421
TOTAL COMPREHENSIVE LOSS	$	(132,029	)	$	(902,859	)

Basic and Diluted Loss per Common Share	$	(0.05	)	$	(0.25	)
Basic and Diluted Weighted Average Common Shares Outstanding		3,697,000			3,647,486

See the notes to the consolidated financial statements

2612 Table of Contents

MEDICO INTERNATIONAL INC.~~CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT~~

										Accumulated
	Common Stock				Additional					Other		Total
	Numberof Shares		Amount		Paid-inCapital		Accumulated Deficit			Comprehensive Loss		Stockholders' Deficit
Balance - December 31, 2014		907,320	$	907	$	-	$	(152,982	)	$	6,398	$	(145,677	)
Adjustment on shares exchange		2,092,680		2,093		69,257		-			-		71,350
Loans forgiven by shareholder		-		-		101,864		-			-		101,864
Net loss		-		-		-		(88,708	)		-		(88,708	)
Foreign currency translation adjustments		-		-		-		-			6,976		6,976
Balance - December 31, 2015		3,000,000		3,000		171,121		(241,690	)		13,374		(54,195	)
Adjustment on shares exchange													-
Issuance of shares		697,000		697		696,303		-			-		697,000
Net loss		-		-		-		(920,010	)		-		(920,010	)
Foreign currency translation adjustments		-		-		-		-			17,421		17,421
Balance - December 31, 2016		3,697,000	$	3,697	$	867,424	$	(1,161,700	)	$	30,795	$	(259,784	)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

										Accumulated
	Common Stock				Additional					Other			Total
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Comprehensive Gain			Stockholders’ Deficit

Balance - December 31, 2015		3,000,000	$	3,000	$	171,121	$	(241,690	)	$	13,374		$	(54,195	)
Issuance of shares		697,000		697		696,303		-			-			697,000
Net loss		-		-		-		(920,010	)		-			(920,010	)
Foreign currency translation adjustments		-		-		-		-			17,421			17,421
Balance - December 31, 2016		3,697,000		3,697		867,424		(1,161,700	)		30,795			(259,784	)
Net loss		-		-		-		(169,115	)		-			(169,115	)
Deconsolidation		-		-		-		-			(67,881	)		(67,881	)
Foreign currency translation adjustments		-		-		-		-			37,086			37,086
Balance - December 31, 2017		3,697,000	$	3,697	$	867,424	$	(1,330,815	)	$	-		$	(459,694	)

See the notes to the consolidated financial statements

27 13 Table of Contents

	Year Ended			Year Ended
	December 31,			December 31,
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(920,010	)	$	(88,708	)
Adjustments to reconcile net loss to net cash from operating activities:
Bad debt		-			7,057
Depreciation		575,689			374,037
Loss on disposal of equipment		18,967			-
Changes in operating assets and liabilities:
Accounts receivable		(152,841	)		(18,769	)
Other receivables		69,000			(69,000	)
Prepaid expenses and deposits		(28,361	)		(91,405	)
Inventory		(29,062	)		(70,557	)
Accounts payable		163,174			362,877
Accrued and other payables		72,703			(133,219	)
Deferred revenue		2,454			-
Net cash (used in) provided by operating activities		(228,287	)		272,313
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment		(438,226	)		(361,286	)
Net cash used in investing activities		(438,226	)		(361,286	)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares		697,000			-
Loans from related parties		147,020			581,503
Repayment of capital lease obligations		(223,777	)		(294,502	)
Net cash provided by financing activities		620,243			287,001
Effects on changes in foreign exchange rate		17,421			6,976
Net increase in cash and cash equivalents		(28,849	)		205,004
Cash and cash equivalents - beginning of period		316,603			111,599
Cash and cash equivalents - end of period	$	287,754		$	316,603
Supplemental Cash Flow Disclosures
Cash paid for interest	$	8,404		$	5,833
Cash paid for income taxes	$	-		$	-
Non-Cash Investing and Financing Activity:
Equipment acquired under capital lease obligations	$	198,264		$	467,404
Loans forgiven by shareholder	$	-		$	101,864
Share exchange	$	-		$	71,350

MEDICO INTERNATIONAL INC.

~~See~~CONSOLIDATED ~~the~~STATEMENTS ~~notes~~OF toCASH ~~the consolidated financial statements~~FLOWS

28 Table of Contents

	Year ended
	December 31,
	2017			2016

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss from continuing operations	$	(35,874	)	$	(100,828	)
Net loss from discontinuing operations		(133,241	)		(819,182	)
Adjustments to reconcile net loss to net cash from operating activities:
Waive of loans from the disposed subsidiary		-			(965,866	)
Loss on disposal of subsidiaries		77,438			-
Forgivess of accounts payable		(5,142	)		-
Changes in operating assets and liabilities:
Accounts payable		22,901			10,221
Changes in operating assets and liabilities of discontinued operations		378,033			801,761
Net cash provided by (used in) operating activities		304,115			(1,073,894	)

CASH FLOWS USED BY INVESTING ACTIVITIES
Sales of investment in subsidiary		(359,066	)		-
Net cash used in investing activities		(359,066	)		-

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares		-			697,000
Loans from related parties		17,865			359,473
Net cash provided by financing activities		17,865			1,056,473

Effects on changes in foreign exchange rate		37,086			17,421

Net change in cash and cash equivalents		-			-
Cash and cash equivalents - beginning of period		-			-
Cash and cash equivalents - end of period	$	-		$	-

Supplemental Cash Flow Disclosures
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

~~MEDICO~~See ~~INTERNATIONAL~~the ~~INC.NOTES~~notes TOto ~~THE~~the ~~CONSOLIDATED~~unaudited ~~FINANCIAL~~consolidated ~~STATEMENTS~~financial statements

Table of Contents

MEDICO INTERNATIONAL INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Nature of Operations

Medico International Inc. (the “Company” or “Medico”), a Nevada corporation, was formed by the owners and principals of Smile More Holdings Pte. Ltd., a Singaporean corporation (“Smile Central”), for the purpose of acting as the holding company for Smile Central and penetrating the U.S. financial markets. Smile Central owns six (6) dental clinics operating in Singapore. Smile Central’s operations were launched in January 2014 with three (3) clinics and in 2015, an additional two (2) clinics were opened. In 2016, one (1) additional dental clinic was opened. Smile Central plans to continue to expand its operations and create additional clinics in Singapore.

On September 19, 2015, the Company issued a total of 3,000,000 shares of common stock pursuant to the Share Exchange Agreement entered into among Medico, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. Pursuant to the Share Exchange Agreement, the Company agreed to issue 3,000,000 shares of its common stock in exchange for all of the issued and outstanding shares of capital stock of Smile Central, 30% of which was owned by Eminent Healthcare Pte. Ltd. and 70% of which was owned by Multi Care Pte. Ltd. The Company’s CFO, Liew Min Hin, owns 100% of Eminent Healthcare Pte. Ltd. The shares were issued pursuant to Section 4(2) of the Securities Act of 1993 (“Securities Act”) and are restricted shares as defined in the Securities Act.

On June 5, 2017, the Company sold all of the issued and outstanding ordinary shares of the Company’s 100% wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation. The Company is currently reviewing and revising its future business plans. To date, the Company has not yet identified its future business plans.

Note 2: Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("“U.S. GAAP"”) on the accrual basis of accounting.

Certain reclassifications have been made to the prior period’s consolidated financial statements to conform to the current period’s presentation.

Principles of Consolidation

The consolidated financial statements ~~include~~have been prepared in accordance with U.S. GAAP on the ~~accounts~~accrual basis of ~~the~~accounting. ~~Company~~The consolidated financials consist of Medico International Inc. and its 7 subsidiaries through June 5, 2017, Smile Central Dental Group (the “Group”) consists of five entities under common control: Smile Central Dental Aljunied Ptd Ld.; ~~All~~Smile ~~intercompany~~Central ~~accounts~~Dental ~~and~~Hougang ~~transactions~~Ptd ~~have~~Ltd.; ~~been~~Smile ~~eliminated~~Central Dental Hougang Central Pte Ltd; Smile Central Dental Jurong Ptd Ltd.; WeSmile ~~currently~~Central ~~have~~Dental noToa ~~investments~~Payoh ~~accounted~~Ptd ~~for~~Ltd.; ~~using~~Smile ~~the~~More ~~equity~~Holdings orPtd ~~cost~~Ltd. ~~methods~~and, ofSmile ~~accounting~~Central Dental Centre Pte Ltd. All significant inter-company accounts and transactions have been eliminated in consolidation.

Functional Currency

The Company'’s functional currency is the Singapore Dollar and reporting currency is the U.S. dollar. All transactions initiated in Singapore ~~Dollar~~Dollars are translated into U.S. dollars in accordance with Accounting Standards Codification (“ASC”) 830-30, "“Translation of Financial Statements,"” as follows:

i)	Assets and liabilities at the rate of exchange in effect at the balance sheet date.

ii)	Equity at historical rates.

iii)	Revenue and expense items at the average rate of exchange prevailing during the period.

Adjustments arising from such translations are included in accumulated other comprehensive gain in stockholders’ deficit.

Table of Contents

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

29 Table of Contents

Cash and Cash Equivalents

Cash and cash equivalents consists of cash and all highly liquid investments with a maturity of three months or less.

The Company maintains its cash accounts primarily with banks located in Singapore and they are all denominated in Singapore dollar.

Accounts Receivables

Accounts receivable consist primarily of receivables from provided services. Management determines the allowance for doubtful accounts based on customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. On a continuing basis, management analyzes delinquent receivables, and once these receivables are determined to be uncollectible, they are written off against an existing allowance account. As of December 31, 2016 and 2015, the Company has determined that an allowance for doubtful accounts is not necessary as all accounts are considered fully collectible.

Inventory

Inventory is stated at the lower of cost or market. Cost is computed using weighted average cost, which approximates actual cost, on a first-in, first-out basis. Inventory on hand is evaluated on an on-going basis to determine if any items are obsolete or in excess of future needs. Items determined to be obsolete are reserved for. The Company provides for the possible inability to sell its inventory by providing an excess inventory reserve. As of December 31, 2016 and 2015 the Company determined that no reserve was required.

Property and Equipment

Property and equipment are stated at cost and are depreciated over their estimated useful lives using the straight-line method. Expenditures for ordinary maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and accumulated depreciation are eliminated from the account and any gain or loss is reflected on the consolidated statements of operations.

Estimated useful lives for computers are 1 ~ 3 years and useful lives for dental equipment, furniture and fittings, office equipment and lab equipment are 3 ~ 5 years. Renovations are included at the lessor of useful life or the life of the lease.

Impairment or Disposal of Long-Lived Assets

The Company evaluates its long-lived assets whenever significant events or changes in circumstances occur that indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted future net cash flows from the operations to which the assets relate, based on management’s best estimates using appropriate assumptions and projections at the time, to the carrying amount of the assets. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss is recognized equal to the amount by which the carrying amount exceeds the estimated fair value of the asset. No such impairment was indicated at December 31, 2016 and 2015.

Fair Value of Financial Instruments Estimates

The Company’s financial instruments including accounts receivable, accounts payable, accrued and other payables and due to related parties are carried at cost, which approximates fair value due to the short-term maturity of these instruments. The recorded value of the Company’s long-term debt approximates its fair value as it bears interest at a floating rate.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk include cash. At times, the Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management monitors the credit rating and concentration of risk with these financial institutions on a continuing basis to mitigate risk.

30 Table of Contents

Taxes Collected and Remitted to Governmental Authorities

The Company reports taxes collected from customers, which are primarily goods and service tax, on a net basis.

Revenue Recognition

Revenues are recognized when services are rendered, amounts are reliably measurable, and collectability is assured. Revenue is presented, net of goods and services tax, rebates and discounts.

Advertising

Advertising costs are expensed as incurred. Advertising costs totaled $53,917 and $13,536 for the years ended December 31, 2016 and 2015, respectively.

Income Taxes

Current income tax liabilities for current and prior years are recognized at the amounts expected to be paid to the tax authorities, using the tax rates (and tax laws) that have been enacted or substantially enacted by the balance sheet date.

Deferred income tax assets/liabilities are recognized for all deductible/taxable temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements except when the deferred income tax assets/liabilities arise from the initial recognition of an asset or liability in a transaction that is not a business combination and at the time of the transaction, affects neither accounting nor taxable profit or loss.

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized.

Deferred income tax assets and liabilities are measured at:

(i) the tax rates that are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled, based on tax rates (and tax laws) that have been enacted or substantially enacted by the balance sheet date; and

(ii) the tax consequence that would follow from the manner in which the Company expects, at the balance sheet date, to recover or settle the carrying amounts of its assets and liabilities.

Current and deferred income taxes are recognized as income or expenses in the consolidated statements of operations.

Table of Contents

Recent Accounting Pronouncements

In ~~December~~September ~~2016~~2017, the FASB (“Financial Accounting Standards Board ~~(FASB~~”) has issued Accounting Standards Update (ASU) No. ~~2016~~2017-2013, “~~Technical~~Revenue ~~Corrections~~Recognition ~~and Improvements to~~ (Topic ~~606~~605), Revenue from Contracts with Customers.” ~~The~~(Topic ~~amendments~~606), ~~affect~~Leases ~~narrow~~(Topic ~~aspects~~840), ofand ~~the~~Leases ~~guidance~~(Topic ~~issued~~842): inAmendments ~~ASU~~to ~~2014-09~~SEC ~~including~~Paragraphs ~~Loan~~Pursuant ~~Guarantee~~to ~~Fees,~~the ~~Contract~~Staff ~~Costs,~~Announcement ~~Provisions~~at ~~for~~the ~~Losses~~July ~~on Construction-Type and Production-Type Contracts~~20, ~~Disclosure~~2017 ofEITF ~~Remaining~~Meeting ~~Performance~~and ~~Obligations,~~Rescission ~~Disclosure~~ of Prior ~~Period~~SEC ~~Performance~~Staff ~~Obligations,~~Announcements ~~Contract~~and ~~Modifications,~~Observer ~~Contract~~Comments.” ~~Asset~~The ~~vs.~~amendments ~~Receivable,~~in ~~Refund~~ASU ~~Liability,~~No. ~~Advertising~~2017-13 ~~Costs,~~amends ~~Fixed~~the ~~Odds~~early ~~Wagering~~adoption ~~Contracts~~date inoption ~~the~~for ~~Casino~~certain ~~Industry,~~companies ~~and~~related ~~Costs~~to ~~Capitalized~~the ~~for~~adoption ~~Advisors~~of toASU ~~Private~~No. ~~Funds~~2014-09 and ~~Public~~ASU ~~Funds~~No. 2016-02. The effective date ~~and~~is ~~transition requirements for~~ the ~~amendments are the~~ same as the effective date and transition requirements for ~~FASB~~the ~~ASC Topic 606. Public entities should apply Topic 606 (and related~~ amendments) for ~~annual~~ASU ~~reporting~~2014-09 ~~periods~~and ~~beginning after December 15, 2017, including interim reporting periods therein. The Company is currently evaluating the potential impact that the adoption of this~~ ASU ~~may have on its consolidated financial statements~~2016-02.

~~Management~~In ~~has~~May ~~considered~~2014, ~~all~~the ~~recent~~FASB issued some accounting ~~pronouncements~~standards ~~issued~~update which modifies the requirements for identifying, allocating, and recognizing revenue related to the achievement of performance conditions under contracts with customers. ~~The~~This ~~Company's~~update ~~management~~also ~~believes~~requires additional disclosure related to the nature, amount, timing, and uncertainty of revenue that ~~these~~is ~~other~~recognized ~~recent~~under ~~pronouncements~~contracts ~~will~~with customers. This guidance is effective for fiscal and interim periods beginning after December 15, 2017 and is required to be applied retrospectively to all revenue arrangements. The adoption of this guidance is not expected to have a ~~material~~significant ~~effect~~impact on the Company'’s consolidated financial statements, as the Company currently has no revenue stream and is unable to estimate future impact, therefore, at this time the impact is considered to be immaterial.

~~31 Table~~In February 2016, the FASB issued ASU No. 2016-02, Leases . The standard requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in its balance sheet a liability to make lease payments (the lease liability) and a right-of-use ~~Contents~~ asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The guidance in ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. The Company’s initial evaluation of its current leases does not indicate that the adoption of this standard will have a material impact on its consolidated statements of operations. The Company expects that the adoption of the standard will have a material impact on its consolidated balance sheets for the recognition of certain operating leases as right-of-use assets and lease liabilities.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

Note 3: Going Concern

These consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future. As of December 31, ~~2016~~2017, the Company has an accumulated deficit of $1,~~161~~330,~~700~~815 since inception and has a working capital deficiency of $1459,~~120,357~~694.

Management'’s plans include raising capital through the equity markets to fund operations and eventually, generating profit through its business; however, there can be no assurance that the Company will be successful in such activities. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classifications of the liabilities that might be necessary should the Company be unable to continue as a going concern.

~~Note~~17 4:Table ~~Property~~of ~~and Equipment~~Contents

	December 31,2016			December 31,2015
Dental equipment	$	1,057,544		$	835,949
Renovation		755,217			525,341
Computer		68,003			60,190
Office equipment		19,258			20,539
Lab equipment		6,679			6,135
Furniture and fittings		3,218			530
		1,909,919			1,448,684
Less accumulated depreciation		(872,263	)		(454,716	)
	$	1,037,656		$	993,968

Note 4: Disposal of Subsidiaries

~~Depreciation~~On ~~expense~~June of5, ~~approximately $576~~2017,~~000~~ ~~and~~the ~~$374,000~~Company ~~was~~closed ~~recorded~~the bytransactions under the ~~Company~~Share ~~for~~Exchange Agreement (“ Share Exchange Agreement”) by and between the ~~years~~Company, ~~ended~~Eminent ~~December~~Healthcare 31Pte. Ltd., ~~2016~~a ~~and~~Singaporean ~~2015~~corporation, ~~respectively~~Multi Care Pte. ~~Approximately~~Ltd., ~~$339~~a Singaporean corporation,~~000~~ and ~~$234~~Targeted Solutions Global Limited,~~000~~ isa ~~included~~United inKingdom Private limited company, for the ~~cost~~sale of ~~services~~all of the issued and ~~approximately~~outstanding ~~$237~~ordinary shares of the Company’s 100% wholly-owned subsidiary,~~000~~ ~~and~~Smile ~~$140~~More Holdings Pte. Ltd.,~~000~~ isa ~~included~~Singaporean incorporation ~~operating~~(the ~~expenses~~“Stock onPurchase”). Prior to the closing of the Stock Purchase, Eminent Healthcare Pte. Ltd. and Multi Care Pte. Ltd. were the Company’s ~~consolidated~~majority ~~statements~~shareholders. ofLiew ~~operations~~Min ~~for~~Hin, the ~~years~~Company’s ~~ended~~former ~~December~~Chief 31Financial Officer and former member of the Board of Directors, ~~2016~~owns 100% of Eminent Healthcare Pte. Ltd., and ~~2015~~is the father of Dr. Daniel Liew, ~~respectively~~the Company’s former Chief Executive Officer and former member of the Board of Directors.

~~Note~~Pursuant 5:to ~~Capital~~the ~~Leases~~share exchange agreement, the Company transferred all of the subsidiary shares to the purchaser and released the Subsidiary from the intra-Company loan of $965,866.

During the year ended December 31, 2017, the Company recorded a loss on disposal of $77,438. The Company ~~leases~~has ~~dental~~no ~~equipment~~continuing ~~under~~involvement ~~non-cancellable~~in ~~capital~~the ~~lease~~operations ~~arrangements~~of Smile More Holdings. The ~~terms~~disposal of ~~those~~Smile ~~capital~~More ~~leases~~Holdings ~~vary~~qualified ~~from~~as 3a todiscontinued 5operation ~~years~~of the Company and ~~annual~~accordingly, ~~interest~~the ~~rates~~Company ~~vary~~has excluded results of Smile More Holdings’ operations from 3%its Statements of Operations and Comprehensive Loss to 7%present this business in discontinued operations.

AsThe following table shows the results of operations of Smile More Holdings for the years ended December 31, ~~2016,~~2017 ~~the~~and ~~future~~2016 ~~minimum~~which ~~lease~~are ~~payments~~included ~~under~~in ~~finance~~the ~~leases~~loss ~~are~~from asdiscontinued ~~follows~~operations:

2017	$	196,782
	Year Ended
2018		118,886
	December 31,
2019		69,589
	2017			2016
Total		385,257
Dental Service Revenue, net	$	3,065,719		$	6,543,428
Amount representing interest payments		(21,003	)
Cost of Services		2,057,063			5,673,813
Present value of future minimum payments		364,254
Gross profit		1,008,656			869,615
Capital lease obligation, current portion		187,171
General and administrative		259,937			383,750
Capital lease obligation, long-term portion	$	177,083
Professional fees		28,154			199,665
Rental		429,677			845,684
Staff costs		334,347			117,415
Depreciation		94,294			236,711
Operating loss		(137,753	)		(913,610	)
Other income		95,164			102,832
Interest expense		(14,530	)		(8,404	)
Income benefit		1,316			-
Loss from discontinued operations, net of tax	$	(55,803	)	$	(819,182	)

32The ~~Table~~following table shows the carrying amounts of ~~Contents~~the major classes of assets and liabilities associated with Smile More Holdings as of the June 5, 2017.

Note 6: Related Parties Transactions

	June 5,
	2017
Cash and cash equivalents	$	359,066
Accounts receivable		1,175,394
Prepaid expenses and deposits		247,086
Supplies		100,177
Property and equipment, net		887,360
Accounts payable		(1,168,613	)
Accrued and other payables		(122,958	)
Due to related parties		(597,259	)
Loans payable		(565,938	)
Capital lease obligations		(168,996	)
Net assets and liabilities		145,319
Accumulated other comprehensive loss		(67,881	)
Loss on disposal	$	77,438

In18 ~~support~~Table of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances were considered temporary in nature and were not formalized by a promissory note.Contents

~~During~~The ~~the~~following ~~years~~table ~~ended~~summarizes ~~December 31, 2016 and 2015,~~ the ~~Company~~carrying ~~received~~amounts ~~net advances~~ of ~~$147,020 and $581,503 by~~ the ~~way~~assets ofand ~~loans~~liabilities from ~~various~~discontinued ~~officers. As of December 31~~operations, ~~2016 and 2015, the Company was obligated to its officers for unsecured, non-interest bearing demand loans with balances totaling $1,150,316 and $1,003,296, respectively.~~

During the year ended December 31, 2015, one of the Company’s officers forgave $101,864 of expenses paid on behalf of the Company, which was recorded as additional paid in capital.

	December 31,		December 31,
	2017		2016
Assets held for sale
Cash and cash equivalents	$	-	$	287,754
Accounts receivable		-		416,658
Prepaid expenses and deposits		-		222,084
Inventory		-		113,229
Property and equipment, net		-		1,037,656
Total assets held for sale	$	-	$	2,077,381

Liabilities held for sale
Accounts payable	$	-	$	616,124
Accrued and other payables		-		186,894
Due to related parties		-		743,369
Deferred revenue		-		2,454
Capital lease obligations - current		-		187,171
Capital lease obligations		-		177,083
Total liabilities held for sale	$	-	$	1,913,095

Note 75: ~~Common~~Related ~~Stock~~Party Transactions

In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances were considered temporary in nature and were not formalized by a promissory note.

During the years ended December 31, 2017 and 2016, the Company received a net amount of $17,865 and $359,473 as advances and loans from various officers for the operating expenses of the Company, respectively. As of December 31, 2017 and 2016, the Company was obligated to its officers for unsecured, non-interest bearing demand loans with balances totaling $424,812 and $406,947, respectively.

Note 6: Equity

The Company is authorized to issue up to 500,000,000 shares of common stock, par value $0.001.

During the year ended December 31, 2016, the Company issued 697,000 shares at $1.00 per share in connection with its registration statement resulting in proceeds of $697,000.

As of December 31, ~~2016~~2017 and ~~2015~~2016, 3,697,000 ~~and 3,000,000~~ shares of common stock were issued and outstanding~~, respectively~~.

~~Note~~19 8:Table ~~Income~~of ~~Taxes~~Contents

~~The~~Note ~~Company~~7: ~~accounts for income taxes in accordance with the provisions of FASB ASC 740, Accounting for Uncertainty in~~ Income Taxes. The Company files income tax returns in Singapore and there are currently no federal income tax examinations underway. The Company’s tax year of 2014 and forward are subject to examination by federal taxing authorities for at least five years.

The Company accounts for income taxes in accordance with the provisions of FASB ASC 740, Accounting for Uncertainty in Income Taxes. The Company files income tax returns in Singapore and there are currently no federal income tax examinations underway. The Company’s tax year of 2015 and forward are subject to examination by federal taxing authorities for at least five years.

The Company accounts for income taxes using an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The ~~provision~~Company ~~for~~is ~~income~~subject ~~taxes~~to ~~includes:~~taxation in the United States.

	2016		2015
Taxes – current	$	-	$	-
Taxes – deferred		-		-
Income tax expenses	$	-	$	-

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”) resulting in significant modifications to existing law. The Company has completed the accounting for the effects of the Act during the year ended December 31, 2017. The Company’s financial statements for the year ended December 31, 2017 reflect certain effects of the Act which includes a reduction in the corporate tax rate from 34% to 21% as well as other changes.

The ~~Company~~provision isfor ~~subject~~refundable tofederal ~~taxation~~income intax at 34% consists of the ~~United~~following ~~States~~for ~~and~~the ~~Singapore.~~periods ending:

The provision for income taxes differs from the amounts which would be provided by applying the statutory income tax rate of 17% in Singapore and 34% in the United States to the net income (loss) before provision for income taxes for the following reasons:

	December 31,
	2017			2016
Federal income tax benefit attributed to:
Net operating loss from continuing operations	$	(12,197	)	$	(35,290	)
Net operating gain from discontinued operations		(13,242	)		(203,865	)
Valuation		25,439			239,155
Net benefit	$	-		$	-

	2016			2015
Computed at the statutory rate	$	312,803		$	30,161
Difference in rates in Singapore		(139,261	)		(5,879	)
Non-deductible expenses		-			-
Change in valuation allowance		(173,542	)		(24,282	)
Actual tax expense	$	-		$	-

The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows:

33 Table of Contents

	December 31,
	2017			2016
Deferred tax asset attributable to:
Net operating loss carry over	$	(25,439	)	$	(239,155	)
Effect of change in the statutory rate		9,726
Less: valuation allowance		15,713			239,155
Net deferred tax asset	$	-		$	-

~~Following~~20 ~~are~~Table ~~the details~~ of ~~deferred tax assets and its valuation allowance:~~Contents

	December 31,2016			December 31,2015
Deferred tax assets
Net operating loss carry forwards	$	1,161,700		$	241,690
Deferred tax asset before valuation allowance		223,831			50,289
Valuation allowance
Beginning balance		(50,289	)		(26,007	)
Changes during the period		(173,542	)		(24,282	)
Ending balance		(223,831	)		(50,289	)
	$	-		$	-

The related deferred tax benefit on the above unutilized tax losses has a full valuation allowance not recognized against it as there is no certainty of its realization. Management has evaluated tax positions in accordance with ASC 740 and has not identified any significant tax positions, other than those disclosed.

~~The~~Due ~~Company~~to ~~has~~the ~~yet~~change toin ~~file~~ownership ~~its~~provisions of the income tax ~~return~~laws ~~with~~of ~~the~~United ~~Inland~~States ~~Revenue~~of ~~Authority~~America, net operating loss carry forwards of ~~Singapore~~approximately $35,874, which expire commencing in fiscal 2035, for ~~the~~federal ~~year~~income oftax ~~assessment~~reporting ofpurposes ~~2016~~are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.

~~Due~~Note to8: ~~the~~Commitments ~~change~~and in ownership provisions of the income tax laws of United States of America, net operating loss carry forwards of approximately $1,161,700, which expire commencing in fiscal 2035, for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.Contingencies

~~Note~~During 9:the ~~Commitments~~normal ~~and~~course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB 450-20-50, Contingencies. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals. As of December 31, 2017, the Company is not aware of any contingent liabilities that should be reflected in the consolidated financial statements.

~~During~~Note ~~the~~9: ~~normal~~Subsequent course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with FASB 450-20-50, Contingencies. The Company evaluates its exposure to the matter, possible legal or settlement strategies and the likelihood of an unfavorable outcome. If the Company determines that an unfavorable outcome is probable and can be reasonably estimated, it establishes the necessary accruals. As of December 31, 2016, the Company is not aware of any contingent liabilities that should be reflected in the consolidated financial statements.Events

~~The~~In ~~Company~~accordance ~~leases~~with ~~space~~ASC ~~for~~855-10, the Company has analyzed its ~~dental~~operations ~~clinics~~subsequent ~~under~~to ~~non-cancelable~~December ~~operating~~31, ~~leases.~~2017 ~~During~~to the ~~years~~date ~~ended~~these ~~December~~financial ~~31,~~statements ~~2016~~were issued and ~~2015,~~has ~~the~~determined ~~Company~~that ~~paid~~it ~~rent~~does ~~expenses~~not ofhave ~~$845,684~~any ~~and~~additional ~~$561,167,~~material ~~respectively.~~subsequent events to disclose in these financial statements.

As21 Table of ~~December 31, 2016, the approximate future aggregate minimum lease payments under the non-cancellable operating leases were as follows:~~Contents

2017	$	790,578
2018		457,567
2019		110,592
	$	1,358,737

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

~~Note~~On ~~10:~~March ~~Subsequent~~6, ~~Events~~2018, we dismissed Accell Audit & Compliance, P.A. (“Accell”) as our company’s independent principal accountant to audit the Company’s financial statements. The decision to change accountants was approved by our board of directors. Our company does not have a standing Audit Committee.

OnOur ~~February~~company’s ~~14,~~independent ~~2017,~~principal accountant’s report on the ~~Company~~financial ~~entered~~statements ~~into~~for ~~four~~each ~~lease~~of ~~agreements~~the ~~for~~past ~~property,~~two ~~plant,~~years ~~and~~did ~~equipment,~~not ~~which~~contain ~~totaled~~an ~~$948,616~~adverse ~~Singapore~~opinion ~~dollars~~or ~~($655,494~~a ~~USD).~~disclaimer heof ~~Company~~opinion, ~~agreed~~and towas ~~make~~not ~~monthly~~qualified ~~payments~~or inmodified ~~regards~~as to ~~these~~uncertainty, ~~agreements~~audit scope, ~~which~~or ~~end~~accounting inprinciples, ~~January~~with ~~2020.~~the exception that:

~~Due~~(i) to the ~~continued~~report ~~consolidated~~dated ~~losses~~June ~~experience~~16, by2017 contained the ~~Company~~following asexplanatory ~~the~~paragraph: ~~result~~“ ofThe ~~the~~accompanying ~~losses~~consolidated offinancial ~~the~~statements ~~Company’s~~have ~~wholly-owned~~been ~~subsidiary,~~prepared ~~Smile~~assuming ~~More~~that ~~Holdings~~the ~~Pte.~~Company ~~Ltd.,~~will acontinue ~~Singaporean~~as ~~corporation~~a ~~(“Smile~~going ~~Central”),~~concern. ~~the~~As ~~Board~~discussed ofin ~~Directors~~Note of3, the Company ~~believed~~has itincurred ~~was~~net inlosses ~~the~~and ~~best~~negative ~~interests~~working ofcapital ~~the~~since ~~Company~~inception. ~~and~~These ~~its~~factors, ~~shareholders~~and tothe ~~dispose~~need offor ~~Smile~~additional ~~Central.~~financing Inin ~~addition,~~order for the Company ~~had~~to ~~provided~~meet ~~Smile~~its ~~Central~~business ~~with over $600~~plans,~~000~~ inraise ~~intra-company~~substantial ~~loans~~doubt (about the ~~“Intra-~~Company’s ~~Loan”)~~ability to continue as a going concern.”; and

~~The~~(ii) ~~Company’s~~the ~~former~~report ~~majority~~dated ~~shareholders~~April 15, ~~Eminent~~2016 ~~Healthcare~~contained ~~Pte.~~the ~~Ltd.~~following ~~and~~explanatory ~~Multi~~paragraph: ~~Care~~“ ~~Pte.~~The ~~Ltd.~~accompanying ~~(the~~consolidated ~~“Majority~~financial ~~Shareholders”),~~statements ~~became~~have ~~shareholders~~been ofprepared assuming that the Company inwill ~~2015~~continue byas ~~exchanging~~a ~~all~~going ofconcern. As discussed in Note 3, the ~~outstanding~~Company ~~share~~has incurred net losses and negative working capital ofsince ~~Smile~~inception. ~~Central~~These ~~(“Smile~~factors, ~~Shares”)~~and the need for ~~3,000,000~~additional ~~shares~~financing ofin order for the Company’s ~~common~~to ~~stock~~meet ~~(the~~its ~~“Medico~~business ~~Shares”)~~plans, ~~and~~raise ~~the~~substantial ~~Majority~~doubt ~~Shareholders~~about ~~desired~~the Company’s ability to ~~re-acquire~~continue ~~the~~as ~~Smile~~a ~~Shares.~~going concern.”

OnDuring ~~June~~our 5,company’s ~~2017,~~two ~~the~~most ~~Company~~recent ~~closed~~fiscal ~~the~~years ~~transactions under the Share Exchange Agreement (“ Share Exchange Agreement”) by~~ and ~~between~~ the ~~Company,~~subsequent ~~Eminent~~interim ~~Healthcare~~periods ~~Pte.~~preceding ~~Ltd.,~~our adismissal ~~Singaporean~~of ~~corporation~~Accell, ~~Multi~~there ~~Care~~were: ~~Pte.~~(i) ~~Ltd.,~~no adisagreements ~~Singaporean~~with ~~corporation,~~Accell ~~and~~on ~~Targeted~~any ~~Solutions~~matter ~~Global~~of ~~Limited,~~accounting aprinciples ~~United~~or ~~Kingdom Private limited company~~practices, ~~for~~financial ~~the~~statement ~~sale~~disclosure ofor ~~all~~auditing ofscope ~~the~~or ~~issued and outstanding ordinary shares of the Company’s 100% wholly-owned subsidiary~~procedure, ~~Smile~~which ~~More Holdings Pte. Ltd.~~disagreements, aif ~~Singaporean~~not ~~corporation~~resolved ~~(the “Stock Purchase”). Prior~~ to the ~~closing~~satisfaction of ~~the Stock Purchase~~Accell, ~~Eminent~~would ~~Healthcare~~have ~~Pte.~~caused ~~Ltd.~~it ~~and~~to ~~Multi~~make ~~Care~~reference ~~Pte.~~to ~~Ltd. were~~ the ~~Company’s~~subject ~~majority~~matter ~~shareholders.~~of ~~Liew Min Hin,~~ the ~~Company’s~~disagreements ~~former~~in ~~Chief~~its ~~Financial~~reports ~~Officer~~on ~~and former member of~~ the ~~Board~~consolidated offinancial ~~Directors,~~statements ~~owns 100%~~ of ~~Eminent Healthcare Pte. Ltd., and is~~ the ~~father of Dr. Daniel Liew, the~~ Company’s; ~~former~~and ~~Chief~~(ii) ~~Executive~~no ~~Officer~~reportable ~~and~~events ~~former~~as ~~member~~described ofin ~~the~~Item ~~Board~~304(a)(1)(v) of ~~Directors~~Regulation S-K.

~~Pursuant~~On toMarch ~~the Share Exchange Agreement~~6, ~~in consideration for transferring the Smile Shares to the Majority Shareholders and waiving the Intra-Company Loan~~2018, ~~the~~we ~~Company~~engaged ~~received~~PLS ~~all~~CPAs ~~of the rights, interests, claim and title in that certain US patent known as “Method for diagnosing malignancy in pelvic tumors”, US Patent No. 6,112,108~~ (~~the~~ “~~Patent~~PLS”), ~~which~~an ~~Targeted~~independent ~~Solutions~~certified ~~Global~~public ~~Limited~~accounting firm, aas ~~United~~our ~~Kingdom~~principal ~~Private~~independent ~~limited~~accountant ~~company (“TSG”) had the right and ability to deliver to the Company and in connection~~ with the ~~closing~~approval of ~~the~~our ~~Share~~board ~~Exchange Agreement, Jiang Chun Yan was appointed as the CEO and sole member~~ of ~~the Company’s Board of Directors~~directors.

InFrom ~~addition~~March 6, ~~under~~2018 ~~the~~through ~~Share~~August ~~Exchange~~1, ~~Agreement~~2018, ~~TSG~~PLS, ~~received~~was ~~from~~ the ~~Majority~~independent ~~Shareholders~~registered ~~the~~public ~~Medico~~accounting ~~Shares~~firm ~~and~~of ~~the~~our ~~Majority~~company. ~~Shareholders~~On ~~received~~August ~~$200~~1,~~000~~ ~~from~~2018, ~~TSG.~~we notified PLS we were terminating it as our independent certifying accountant.

~~The~~PLS ~~effect~~has not provided our company with an audit report, however, none of ~~the~~our ~~transactions~~previous ~~set~~audit ~~forth~~reports, in particular the ~~Share~~audit ~~Exchange~~reports ~~Agreement~~for isthe ~~that~~fiscal ~~commencing~~years ~~June~~ended 5December 31, ~~2017~~2016 ~~the~~and ~~Company~~December ~~will~~31, no2015, ~~longer~~contained ~~own~~any ~~and~~adverse ~~operate~~opinion ~~dental~~or ~~clinics~~disclaimer inof ~~Singapore~~opinion, ~~but~~nor ~~will~~were ~~focus~~qualified ~~its~~or ~~efforts~~modified inas ~~the~~to ~~area~~uncertainty, ofaudit ~~cancer~~scope, ~~diagnostics~~or ~~tools~~accounting inprinciples, ~~connection~~except ~~with~~for a going concern qualification on the ~~Patent~~Company’s financial statements for the fiscal years ended December 31, 2016 and 2015.

34From ~~Table~~March 6, 2018 to August 1, 2018, there were no disagreements (as defined in Item 304 of ~~Contents~~Regulation S-K) with PLS on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PLS would have caused it to make reference in connection with its opinion to the subject matter of the disagreement. Further, during the period of March 6, 2018 to August 1, 2018, there were no reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).

~~Item~~On 9August 1, 2018, we engaged Accell Audit & Compliance, P.A. ~~Changes~~(“Accell”), Inan ~~and~~independent ~~Disagreements~~registered public accounting firm, as our principal independent accountant with ~~Accountants~~the onapproval ~~Accounting~~of ~~and~~our ~~Financial~~board ~~Disclosure~~of directors.

~~None.~~22 Table of Contents

Item 9A. Controls and Procedures

~~Management’s~~Evaluation ~~Report~~of ~~on Internal Controls over Financial~~ Disclosure Controls and Procedures

Disclosure ~~Controls~~controls and ~~Procedures.~~procedures ~~Our~~are ~~Chief~~designed ~~Executive~~to ~~Officer~~ensure ~~and~~that ~~Chief~~information ~~Financial~~required ~~Officer~~to be disclosed in the reports filed or submitted under the Exchange Act is recorded, ~~have~~processed, ~~evaluated~~summarized and reported, within the ~~effectiveness~~time ofperiod ~~our~~specified ~~disclosure~~in the SEC’s rules and forms. Disclosure controls and procedures ~~(as~~include, ~~such~~without ~~term~~limitation, iscontrols ~~defined~~and procedures designed to ensure that information required to be disclosed in ~~Rules~~the ~~13a-15(e)~~reports filed under the Exchange Act is accumulated and ~~15d-15~~communicated to management, including our chief executive officer and chief financial officer (eour principal executive officer, principal financial officer and principal accounting officer). We carried out an evaluation, under the ~~Securities~~supervision ~~Exchange~~and ~~Act~~with the participation of ~~1934~~our management, asincluding ~~amended~~our president (~~the~~our ~~“Exchange~~principal ~~Act”~~executive officer, principal financial officer and principal accounting officer)), inof ~~connection~~the ~~with~~effectiveness of the ~~preparation~~design and operation of ~~this~~our ~~Annual~~disclosure ~~Report~~controls onand ~~Form~~procedures ~~10-K~~as of December 31, 2017. Based upon the evaluation of our disclosure controls and procedures as of the December 31, ~~2016~~2017, our management concluded that our disclosure controls and procedures were not effective because of the identification of a material weakness in our internal control over financial reporting which is identified below, and we view as an integral part of our disclosure controls and procedures.

~~Based~~Management’s Report on ~~the~~Internal ~~review~~Control ~~described~~over ~~above, our Chief Executive Officer and Chief~~ Financial ~~Officer determined that our disclosure controls and procedures were effective as of the end of the period covered by this report.~~Reporting

~~Internal~~Our ~~Control~~management ~~Over Financial Reporting. Management~~ is responsible for establishing and maintaining adequate internal control over financial reporting, (as such term is defined in ~~Rules 13a-15(f)~~Exchange ~~and~~Rule ~~15d~~13a-15(f). ~~under~~Our ~~the~~internal ~~Exchange~~control ~~Act)~~over ~~to provide reasonable assurance regarding the reliability of our~~ financial reporting ~~and~~is ~~the~~a ~~preparation~~process ~~of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A control system, no matter how well~~ designed ~~and~~to ~~operated, can~~ provide ~~only~~ reasonable, ~~not absolute,~~ assurance ~~that~~to ~~the~~our ~~control~~management ~~system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints,~~ and ~~the~~board ~~benefits~~ of ~~controls~~directors ~~must~~regarding ~~be considered relative to their costs. In addition, because of~~ the ~~inherent~~reliability ~~limitations in all control systems, no evaluation~~ of ~~controls~~financial ~~can~~reporting ~~provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues~~ and ~~instances of fraud, if any, have been detected. These inherent limitations include~~ the ~~realities~~preparation ~~that judgments in decision-making can be faulty and that breakdowns can occur because~~ of ~~simple error or mistake. Controls can also be circumvented by~~ the ~~individual~~financial ~~acts~~statements offor ~~some~~external ~~persons,~~purposes byin ~~collusion~~accordance ofwith ~~two~~accounting orprinciples ~~more~~generally ~~people,~~accepted ~~or by management override of the controls. The design of any system of controls is based~~ in ~~part on certain assumptions about~~ the ~~likelihood~~United ofStates ~~future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections~~ of ~~any evaluation of controls effectiveness to future periods are subject to risks~~America. ~~Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.~~

Our ~~management assessed our~~ internal control over financial reporting asincludes ofthose ~~December~~policies ~~31,~~and ~~2016~~procedures ~~based~~that on(i) ~~criteria~~pertain ~~established~~to the maintenance of records that, in ~~Internal~~reasonable ~~Control—Integrated~~detail, ~~Framework~~accurately ~~issued~~and byfairly reflect the ~~Committee~~transactions and dispositions of ~~Sponsoring~~our ~~Organizations~~assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of ~~the~~financial ~~Treadway~~statements ~~Commission.~~in ~~Based~~accordance onwith ~~such~~accounting ~~assessment~~principles generally accepted in the United States of America, and our ~~management~~receipts ~~concluded~~and ~~that~~expenditures ~~our~~of ~~internal~~are ~~control~~being ~~over~~made ~~financial~~only ~~reporting~~in ~~was~~accordance ~~effective~~with asauthorizations of ~~December~~our ~~31,~~management ~~2016~~and todirectors; and (iii) provide reasonable assurance regarding ~~the~~prevention ~~reliability~~or timely detection of ~~financial~~unauthorized ~~reporting~~acquisition, ~~and~~use, ~~the~~or ~~preparation~~disposition of ~~financial~~our ~~statements~~assets ~~for~~that ~~external~~could ~~reporting~~have ~~purposes~~a inmaterial ~~accordance~~effect ~~with~~on ~~U.S.~~the ~~generally~~financial ~~accepted accounting principles~~statements.

35Because ~~Table~~of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. All internal control systems, no matter how well designed, have inherent limitations, including the possibility of ~~Contents~~human error and the circumvention of overriding controls. Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with respect to financial statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

~~This~~The ~~annual~~material ~~report~~weakness onrelates ~~Form~~to ~~10-K~~the ~~does~~lack ~~not~~of ~~include~~segregation anof ~~attestation~~duties ~~report~~in our financial reporting process and our utilization of ~~the~~outside ~~Company’s~~third ~~registered~~party ~~public~~consultants. ~~accounting~~We ~~firm~~do ~~regarding~~not ~~internal~~have ~~control~~a ~~over~~separately ~~financial~~designated ~~reporting~~audit committee. ~~Management’s~~This ~~report~~weakness ~~was~~is ~~not~~due ~~subject~~ to ~~attestation~~our bylack ~~the~~of ~~Company’s~~sufficient ~~registered~~working ~~public~~capital ~~accounting~~to ~~firm~~hire ~~pursuant~~additional tostaff. ~~temporary~~To ~~rules~~remedy ofthis ~~the~~material ~~Securities~~weakness, ~~and~~we ~~Exchange~~intend ~~Commission~~to ~~that~~engage ~~permit~~an ~~the~~internal ~~Company~~accounting staff to ~~provide~~assist ~~only~~with ~~management’s~~financial ~~report~~reporting inas ~~this~~soon ~~annual~~as ~~report~~our onfinances ~~Form~~will ~~10-K~~allow.

Changes in Internal ~~Controls~~Control Over Financial Reporting

There ~~were~~have been no changes in our internal ~~control~~controls over financial reporting that occurred during the ~~fourth~~year ~~quarter~~ ended December 31, ~~2016,~~2017 that have materially ~~affected,~~ or are reasonably likely to materially affect, our internal ~~control~~controls over financial reporting.

Item 9B. Other Information.

~~On June 5, 2017, the Company closed the transactions under the Share Exchange Agreement (“ Share Exchange Agreement”) by and between the Company, Eminent Healthcare Pte~~None. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited company, for the sale of all of the issued and outstanding ordinary shares of the Company’s 100% wholly-owned subsidiary, Smile More Holdings Pte. Ltd., a Singaporean corporation (the “Stock Purchase”).

~~Pursuant~~23 toTable ~~the Share Exchange Agreement, in consideration for transferring the Smile Shares to the Majority Shareholders and waiving the Intra-Company Loan, the Company received all~~ of the rights, interests, claim and title in that certain US patent known as “Method for diagnosing malignancy in pelvic tumors”, US Patent No. 6,112,108 (the “Patent”), which Targeted Solutions Global Limited, a United Kingdom Private limited company (“TSG”) had the right and ability to deliver to the Company and in connection with the closing of the Share Exchange Agreement, Jiang Chun Yan was appointed as the CEO and sole member of the Company’s Board of Directors. Contents

InPART ~~addition, under the Share Exchange Agreement, TSG received from the Majority Shareholders the Medico Shares and the Majority Shareholders received $200,000 from TSG.~~ III

~~The~~Item ~~effect~~10. ~~of the transactions set forth in the Share Exchange Agreement is that commencing June 5~~Directors, ~~2017~~Executive ~~the~~Officers ~~Company will no longer own~~ and ~~operate~~Corporate ~~dental clinics in Singapore but will focus its efforts in the area of cancer diagnostics tools in connection with the Patent.~~Governance

36All ~~Table~~directors of ~~Contents~~our company hold office until the next annual meeting of the security holders or until their successors have been elected and qualified. The officers of our company are appointed by our board of directors and hold office until their death, resignation or removal from office. Our directors and executive officers, their ages, positions held, and duration as such, are as follows:

PART III

Name

Position Held with the Company

Age

Date First Elected

or Appointed

Jiang Chun Yan

Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director

June 5, 2017

~~Item~~Business ~~10. Directors, Executive Officers, Promoters and Control Persons of the Company~~Experience

(The following is a) –brief ~~(b)~~account ~~Identification~~of the education and business experience during at least the past five years of ~~Directors~~each director, executive officer and ~~Executive~~key ~~Officers~~employee of our company, indicating the person’s principal occupation during that period, and the name and principal business of the organization in which such occupation and employment were carried out.

~~The~~Jiang ~~Company: The~~Chun ~~following~~Yan ~~table~~- ~~identifies~~Chief ~~all of the members of the Company’s Board of Directors and its~~ Executive ~~Officers.~~Officer, ~~The~~Chief ~~members~~Financial ofOfficer, ~~the~~Treasurer, ~~Board~~Secretary ~~serve until the next annual meeting~~ and ~~a successor is appointed and qualified, or until resignation or removal~~director.

Name		Age		Positions Held		Date of Appointment
Jiang Chun Yan		34		Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Member of the Board of Directors		June 5, 2017

Jiang Chun Yan holds an MBA. He completed his studies at the University of Shanghai in 2010. He worked as a manager at Shindo Industries in South Korea from 2011 until 2016. He spent 2016 and 2017 looking for new opportunities prior to becoming an officer and director of the Company.

~~(c)~~Our ~~Identification~~company ofbelieves ~~certain~~that ~~significant employees~~Mr. Yan’s professional background experience gives him the qualifications and skills necessary to serve as a director of our company.

~~The~~Term ~~Company~~of ~~currently does not have any employees.~~Office

~~(d)~~Our ~~Family~~directors ~~relationships~~are appointed for a one-year term to hold office until the next annual general meeting of our stockholders or until removed from office in accordance with our bylaws. ~~None~~Our officers are appointed by our board of directors and hold office until removed by the board.

~~(e)~~All ~~Business~~officers ~~experience~~and directors listed above will remain in office until the next annual meeting of our stockholders, and until their successors have been duly elected and qualified. There are no agreements with respect to the election of Directors. We have not compensated our Directors for service on our Board of Directors, any committee thereof, or reimbursed for expenses incurred for attendance at meetings of our Board of Directors and/or any committee of our Board of Directors. Officers are appointed annually by our Board of Directors and each Executive Officer serves at the discretion of our Board of Directors. We do not have any standing committees. Our Board of Directors may in the future determine to pay Directors’ fees and reimburse Directors for expenses related to their activities.

~~Jiang~~Employment ~~Chun Yan - Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Member of the Board of Directors~~Agreements

~~Jiang~~We ~~Chun~~have ~~Yan~~no ~~holds~~formal anemployment ~~MBA.~~agreements Hewith ~~completed~~any ~~his studies at the University~~ of ~~Shanghai~~our indirectors ~~2010.~~or ~~He worked as a manager at Shindo Industries in South Korea from 2011 until 2016~~officers. ~~He spent 2016 and 2017 looking for new opportunities prior to becoming an officer and director of the Company.~~

~~(f)~~Family ~~Involvement in certain legal proceedings.~~Relationships

~~None~~There ofare ~~the~~no ~~Company’s~~family ~~executive~~relationships ~~officers~~between orany ~~directors~~of ~~have~~our ~~been~~directors, ~~involved~~executive inofficers ~~any~~and ~~legal~~proposed ~~proceedings~~directors ~~during~~or ~~the~~executive ~~past five (5) years~~officers.

3724 Table of Contents

~~(g)~~Involvement ~~Promoters~~in ~~and~~Certain ~~control~~Legal ~~persons.~~Proceedings

AsTo ~~a result of~~ the ~~Stock~~best ~~Purchase Agreement, Targeted Solutions Global Limited, a United Kingdom Private limited company (“TSG”), owns 3,000,000 shares~~ of ~~the~~our ~~Company’s common stock~~knowledge, ~~which~~none ~~represents 81.14%~~ of ~~the~~our ~~total~~directors ~~shares~~or ~~issued~~executive ~~and~~officers ~~outstanding. Therefore~~has, ~~TSG is a controlling shareholder of the Company. TSG has not been a party to any legal proceedings at any time~~ during the past ~~five~~ten ~~(5)~~ years.:

1. been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences); 2. had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time; 3. been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity; 4. been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; 5. been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or 6. been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 163(a)(26) ~~Beneficial~~of ~~Ownership~~the ~~Reporting~~Exchange ~~Compliance~~Act (15 U.S.C. 78c(a)(26)), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29)), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

~~Not~~Compliance ~~applicable.~~with Section 16(A) of the Securities Exchange Act of 1934

~~Code~~Our common stock is not registered pursuant to Section 12 of ~~Ethics~~the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, our executive officers and directors and persons who own more than 10% of a registered class of our equity securities are not subject to the beneficial ownership reporting requirements of Section 16(1) of the Exchange Act.

~~We do not currently have a~~ Code of Ethics in place for the Company. Our business operations are not complex and are very limited. The Company seeks advice and counsel from outside experts such as our lawyers and accountants on matters relating to corporate governance and financial reporting.

~~Audit~~We ~~Committee~~have not adopted a Code of Business Conduct and Ethics.

WeBoard doand ~~not have an Audit~~ Committee. The Company's board of directors perform some of the same functions of an Audit Committee, such as: recommending a firm of independent certified public accountants to audit the financial statements; reviewing the auditors' independence, the financial statements and their audit report; and reviewing management's administration of the system of internal accounting controls. The Company does not currently have a written audit committee charter or similar document.Meetings

Our board of directors held no formal meetings during the year ended December 31, 2017. All proceedings of the board of directors were conducted by resolutions consented to in writing by all the directors and filed with the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on that resolution at a meeting of the directors are, according to the Nevada General Corporate Law and our Bylaws, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

Table of Contents

Nomination Process

As of December 31, 2017, we did not effect any material changes to the procedures by which our shareholders may recommend nominees to our board of directors. Our board of directors does not have a policy with regards to the consideration of any director candidates recommended by our shareholders. Our board of directors has determined that it is in the best position to evaluate our company’s requirements as well as the qualifications of each candidate when the board considers a nominee for a position on our board of directors. If shareholders wish to recommend candidates directly to our board, they may do so by sending communications to the president of our company at the address on the cover of this annual report.

Audit Committee

Currently our audit committee consists of our entire board of directors. We do not have a standing audit committee as we currently have limited working capital and minimal revenues. Should we be able to raise sufficient funding to execute our business plan, we will form an audit, compensation committee and other applicable committees utilizing our directors’ expertise.

Audit Committee Financial Expert

Currently our audit committee consists of our entire board of directors. We do not currently have a director who is qualified to act as the head of the audit committee.

Item 11. Executive Compensation

The Company was incorporated in September 2015 and therefore has not paid any salaries to its executive officers. Currently, the Company’s executive officers are compensated only for the services that they provide to Smile Central and the various clinics as detailed below. The Company does not have any plans to the executive officers salaries.

The particulars of the compensation paid to the following persons:

	(a)	our principal executive officer;

	(b)	each of our two most highly compensated executive officers who were serving as executive officers at the end of the years ended December 31, 2017 and 2016; and

	(c)	up to two additional individuals for whom disclosure would have been provided under (b) but for the fact that the individual was not serving as our executive officer at the end of the years ended December 31, 2017 and 2016, who we will collectively refer to as the named executive officers of our company, are set out in the following summary compensation table, except that no disclosure is provided for any named executive officer, other than our principal executive officers, whose total compensation did not exceed $100,000 for the respective fiscal year:

38 Table of Contents

SUMMARY COMPENSATION TABLE
Name and Principal Position	Year	Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensa-tion ($)		Change in Pension Value and Nonqualified Deferred Compensa-tion Earnings ($)		All Other Compensa-tion ($)		Total ($)
Jiang Chun Yan⁽¹⁾ CEO, CFO,	2017		0		0		0		0		0		0		0		0
Secretary and Director	2016		0		0		0		0		0		0		0		0

________

(1) Mr. Yan was appointed, CEO, CFO, Secretary and Director on June 5, 2017.

Table of Contents

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.

Grants of Plan-Based Awards

During the fiscal year ended December 31, 2017 we did not grant any stock options.

Option Exercises and Stock Vested

During our fiscal year ended December 31, 2017 there were no options exercised by our named officers.

Compensation of Directors

We do not have any agreements for compensating our directors for their services in their capacity as directors, although such directors are expected in the future to receive stock options to purchase shares of our common stock as awarded by our board of directors.

No compensation was paid to non-employee directors for the year ended December 31, 2017.

Pension, Retirement or Similar Benefit Plans

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. We have no material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the discretion of the board of directors or a committee thereof.

Indebtedness of Directors, Senior Officers, Executive Officers and Other Management

None of our directors or executive officers or any associate or affiliate of our company during the last two fiscal years, is or has been indebted to our company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently outstanding.

Table of Contents

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth, as of December 5, 2018, certain information ~~concerning~~with ~~the~~respect ~~number~~to ofthe ~~shares~~beneficial ownership of our common ~~stock~~and ~~owned~~preferred ~~beneficially~~shares asby ofeach ~~June~~shareholder 5,known ~~2017~~by ~~(after~~us ~~giving effect~~ to be the ~~transactions~~beneficial ~~under~~owner ~~the~~of ~~Stock~~more ~~Purchase~~than ~~Agreement)~~5% ~~by:~~of ~~(i)~~our ~~each~~common ~~person~~and ~~(including~~preferred ~~any~~shares, ~~group)~~as ~~known~~well toas usby toeach ~~own~~of ~~more~~our ~~than~~current ~~five~~directors ~~percent~~and ~~(5%)~~executive ofofficers ~~any~~as ~~class~~a ofgroup. ~~our~~Each person has sole voting ~~securities,~~and ~~(ii)~~investment ~~members~~power ofwith ~~our~~respect ~~Board~~to the shares of ~~Directors,~~common and orpreferred ~~(iii)~~stock, ~~our~~except ~~executive~~as ~~officers~~otherwise indicated. ~~Unless~~Beneficial ~~otherwise~~ownership ~~indicated,~~consists ~~the~~of ~~stockholder~~a ~~listed~~direct ~~possesses~~interest ~~sole~~in ~~voting~~the ~~and~~shares ~~investment~~of ~~power~~common ~~with~~and ~~respect~~preferred tostock, ~~the~~except ~~shares~~as ~~shown~~otherwise indicated.

Title of Class	Name and Address of beneficial owner	Amount and nature of beneficial ownership(1)			Percent of class
Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percentage of Class(1)
Common Stock	Targeted Solutions Global Limited The Bristol Office, 2nd Fl., 5 High Street, Westbury on Trym [Bristol, United Kingdom		3,000,000			81.14	%
Jiang Chun Yan 187 E. Warm Springs Road, Suite B273Las Vegas, NV 89119	Nil	Nil
Common Stock	Jiang Chun Yan (2) The Bristol Office, 2nd Fl., 5 High Street, Westbury on Trym Bristol, United Kingdom		-0-			0	%
Directors and Executive Officers as a Group	Nil	Nil
Targeted Solutions Global Limited Gf Ro 5 High Street Westburry On Trym, BristolUnited Kingdom, BS9 3BY	3,000,000 Common / Direct		81.15	%

(1) A beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person's actual ownership or voting power with respect to the number of shares of common stock actually outstanding on April 1, 2016.__________

(1) Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of ~~June~~outstanding 12shares of any person as shown in this table does not necessarily reflect the person’s actual ownership or voting power with respect to the number of shares of common stock actually outstanding on December 5, ~~2017~~2018. As of December 5, 2018 there were 3,697,000 shares of our company’s common stock issued and outstanding.

~~(2)~~Changes ~~Jiang~~in ~~Chun Yan was appointed an officer and director of the Company effective June 5, 2017.~~ Control

39We ~~Table~~are unaware of ~~Contents~~any contract or other arrangement or provisions of our Articles or Bylaws the operation of which may at a subsequent date result in a change of control of our company. There are not any provisions in our Articles or Bylaws, the operation of which would delay, defer, or prevent a change in control of our company.

The Company has not adopted any equity compensation plans and does not anticipate adopting any equity compensation plans in the near future. Notwithstanding the foregoing, because the Company has limited cash resources at this time, it may issue shares or options to or enter into obligations that are convertible into shares of common stock with its employees and consultants as payment for services or as discretionary bonuses. The Company does not have any arrangements for such issuances or arrangements at this time.

OnExcept ~~September~~as ~~19,~~disclosed ~~2015~~herein, weno ~~issued a total of 3~~director,~~000,000~~ ~~shares~~executive ~~of common stock pursuant to the Share Exchange Agreement entered into among us~~officer, ~~Eminent~~shareholder ~~Healthcare~~holding ~~Pte.~~at ~~Ltd.~~least ~~and~~5% ~~Multi Care Pte. Ltd., which were the owners~~ of ~~Smile More Holdings Pte. Ltd. Pursuant to the Share Exchange Agreement, we agreed to issue 3,000,000~~ shares of our common stock, inor ~~exchange~~any ~~for~~family ~~all~~member ofthereof, ~~the~~had ~~issued~~any ~~and~~material ~~outstanding~~interest, ~~shares~~direct ofor ~~capital~~indirect, ~~stock~~in ofany ~~Smile More Holdings Pte. Ltd. (“Smile Shares”)~~transaction, ~~30%~~or ofproposed ~~which~~transaction ~~was~~since ~~owned~~the byyear ~~Eminent~~ended ~~Healthcare~~December ~~Pte.~~31, ~~Ltd.~~2017, ~~and~~in ~~70% of~~ which ~~was~~the ~~owned~~amount byinvolved ~~Multi~~in ~~Care~~the ~~Pte.~~transaction ~~Ltd.~~exceeded ~~Our~~or ~~former~~exceeds ~~CFO,~~the ~~Liew~~lesser ~~Min~~of ~~Hin~~$120,000 ~~owns~~or ~~100%~~one ofpercent ~~Eminent Healthcare Pte. Ltd. The shares were issued pursuant to Section 4(2)~~ of the ~~Securities~~average ~~Act and are restricted shares as defined in the Securities Act. As part~~ of ~~the~~our ~~Stock~~total ~~Purchase~~assets ~~Agreement,~~at the ~~Company~~year-end ~~transferred~~for the ~~Smile~~last ~~Shares~~three tocompleted ~~Eminent~~fiscal ~~Healthcare Pte~~years. ~~Ltd. and Multi Care Pte. Ltd.~~

In28 ~~support~~Table of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances were considered temporary in nature and were not formalized by a promissory note.Contents

~~During~~Director the years ended December 31, 2016 and 2015, the Company received net advances of $147,020 and $581,503 by the way of loans from various officers. As of December 31, 2016 and 2015, the Company was obligated to its officers for unsecured, non-interest bearing demand loans with balances totaling $1,150,316 and $1,003,296, respectively.Independence

~~During~~We ~~the~~currently ~~year~~act ~~ended~~with ~~December 31, 2015,~~ one ~~of the Company’s officers forgave $101~~director,~~864~~ ofJiang ~~expenses~~Chun ~~paid on behalf of the Company, which was recorded as additional paid in capital~~Yan.

We have determined we do not have an independent director, as that term is used in Rule 4200(a)(15) of the Rules of National Association of Securities Dealers.

Currently our audit committee consists of our entire board of directors. We currently do not have nominating, compensation committees or committees performing similar functions. There has not been any defined policy or procedure requirements for shareholders to submit recommendations or nomination for directors.

From inception to present date, we believe that the members of our audit committee and the board of directors have been and are collectively capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting.

Item 14. Principal Accounting Fees and Services

The aggregate fees billed byfor ~~our~~the ~~independent~~most ~~auditors,~~recently ~~Accell~~completed ~~Audit~~fiscal &year ~~Compliance~~ended December 31, ~~P.A.~~2017 and for fiscal year ended December 31, 2016 for professional services rendered by the principal accountant for the audit of our annual financial statements ~~for~~and review of the ~~years~~financial ~~ended~~statements ~~December~~included ~~31,~~in ~~2016~~our quarterly reports on Form 10-Q and ~~2015~~services that are normally provided ~~below.~~by the accountant in connection with statutory and regulatory filings or engagements for these fiscal periods were as follows:

Fee Category	Year Ended December 31,2016		Year Ended December 31,2015
	Year Ended
Audit Fees	$	34,500	$	21,500
	December 31, 2017		December 31, 2016
Audit-Related Fees		-		-
Audit Fees	$	34,500	$	34,500
Tax Fees		-		-
Audit Related Fees	Nil		Nil
All Other Fees		-		-
Tax Fees	Nil		Nil
Total Fees	$	34,500	$	21,500
All Other Fees	Nil		Nil
Total	$	34,500	$	34,500

~~Audit~~Our ~~committee~~board ~~policies~~of &directors ~~procedures~~pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by the board of directors either before or after the respective services were rendered.

~~The~~Our ~~company~~board ~~does~~of ~~not~~directors ~~currently~~has ~~have~~considered athe ~~standing~~nature ~~audit~~and ~~committee.~~amount ~~The~~of ~~above~~fees billed by our independent auditors and believes that the provision of services ~~were~~for ~~approved~~activities byunrelated to the ~~company’s~~audit ~~Board~~is ofcompatible ~~Directors~~with maintaining our independent auditors’ independence.

4029 Table of Contents

PART IV

Item 15. Exhibits, Financial Statement Schedules

The following exhibits are included as part of this report by reference:

(a)	Financial Statements

		(1)	Financial statements for our company are listed in the index under Item 8 of this document.

		(2)	All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

(b)	Exhibits

10.1	Share Exchange Agreement, dated May 29, 2017, by and between the Medico International Inc., Eminent Healthcare Pte. Ltd., a Singaporean corporation, Multi Care Pte. Ltd., a Singaporean corporation, and Targeted Solutions Global Limited, a United Kingdom Private limited company.
Exhibit Number		Description
31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
(31)		Rule 13a-14 (d)/15d-14d) Certifications
32.1	Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.
31.1*		Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1**		Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101**		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

~~41 Table of Contents~~________

~~SIGNATURES~~* Filed herewith.

~~Pursuant~~** toFurnished ~~the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.~~herewith

	MEDICO INTERNATIONAL INC.
Dated June 19, 2017	By:	/s/ Jiang Chun Yan
	Name:	Jiang Chun Yan
	Title:	Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Financial and Accounting Officer), and Director

Table of Contents

~~In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.~~SIGNATURES

Signatures	Title	Date
/s/ Jiang Chun Yan	Chief Executive Officer, Chief Financial Officer, and Director	June 19, 2017
Jiang Chun Yan

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

		MEDICO INTERNATIONAL INC.
		(Registrant)

Dated: January 14, 2019		/s/ Jiang Chun Yan
		Jiang Chun Yan
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Dated: January 14, 2019		/s/ Jiang Chun Yan
		Jiang Chun Yan
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · Medico International Inc.